

A surgeon in blue scrubs and a surgical mask is focused on a procedure in an operating room. The background is slightly blurred, showing other medical staff in similar attire.

Kellogg Cancer Center

Annual Report
2025

Personalized,
Precision
Medicine

Building on a Legacy of Excellence

As we continue to advance the Endeavor Health Cancer Institute Kellogg Cancer Center, we lean into our history of providing excellent community-connected care with pride and renewed dedication to superior care for every individual patient.

While Endeavor Health Cancer Institute is our new name, our commitment to personalized and pioneering care has not changed. Patients will continue to benefit from our expanded offerings as we integrate the best parts of our system and tap collaborative expertise from our broader pool of subspecialized leading physicians.


As we continue to expand our reach, we are pleased to welcome important new clinical leaders, including Ted James, MD, the Endeavor Health Cancer Institute System Physician Executive. He and others featured in this report will bring additional depth and expertise, particularly in the critical areas of immunotherapy, bioinformatics, survivorship and whole person care, precision oncology, quality improvement and research innovation. At the same time, we pay tribute to our history and the pioneering leadership of Janardan Khandekar, MD, whose vision and tireless commitment helped create our institute model, bringing academic rigor to a community cancer program.

We will remain a leader in personalized medicine, and our Davis Family Center for Preventive Genomics will continue to leverage our role as a leader in harnessing genetics for early disease detection and optimal individualized therapies. Our collaborative team of physician-scientists is already improving outcomes for patients and driving innovative new standards of care.

A commitment to academics has remained a cornerstone of who we are, with expanded fellowship and residency programs underscoring our academic reputation and affiliation with the University of Chicago Pritzker School of Medicine. Training the next generation of physician leaders is a vital element of our mission, which also brings the benefit of shared clinical and research initiatives to our patients. Our inaugural class of hematology/oncology fellows will begin training in July 2026.

These programs and our myriad of services have always relied on generous philanthropy, an essential element of our cancer program since its founding days. Charitable donations remain critical to our efforts to advance lifesaving research and vital patient support programs. We're exceptionally grateful to our many donors, particularly patients and family members whose meaningful generosity is more crucial than ever.

We're pleased to present this report that highlights some of the important advancements and innovative progress of the Endeavor Health Cancer Institute. And we are truly grateful for your interest in our work to provide transformative care for cancer patients and their families.



Bruce Brockstein, MD
Medical Director, Endeavor Health Cancer Institute Kellogg Cancer Center
Kellogg-Scanlon Chair of Oncology
Physician Executive, Endeavor Health Medical Group-Hematology/Oncology

Seth Krantz, MD
Division Head, Thoracic Surgery, Endeavor Health
Department of Surgery
Chairman, NorthShore Cancer Committee



ASCO QOPI
Certification Program



Contents

Legacy of Excellence

Noteworthy Retirements
Leadership Announcements
Major Recruits

PAGE 3

Improving Outcomes

PAGE 8

Personalized Medicine

Thriving Patients

PAGE 9

Multidisciplinary Breast Cancer Program

PAGE 14

Research Highlights

PAGE 15

Essential Charitable Support

PAGE 18

Academic Leadership Roles and Awards

PAGE 19

Clinical Trials

Oncology Trials
Surgical Trials

PAGE 21

Research Publications 2025

PAGE 25

Physician Directory

PAGE 36

Locations

PAGE 41

1976

Oncology Center funded by The Auxiliary of NorthShore University HealthSystem established at Evanston Hospital, an innovative program based on ambulatory care

1980

Clinical trials program begins with breast cancer study

1981

Kellogg Cancer Center founded at Evanston Hospital with a generous gift from the Kellogg family

1983

Community Clinical Oncology Program (CCOP) funding received for National Cancer Institute–sponsored clinical trials

1991–2003

Study site/participant for National Institutes of Health (NIH) Women’s Health Initiative for breast and other cancers

1994

Glenbrook Hospital Kellogg Cancer Center opened

1997

Center for Medical Genetics established

2000

Highland Park Hospital Kellogg Cancer Center opened

2010

New four-story Kellogg Cancer Center opens at Evanston Hospital, doubling space

New Kellogg Cancer Center opens at John and Carol Walter Ambulatory Care Center, Glenbrook Hospital

2012

Highland Park Hospital Kellogg Cancer Center moved to current space in Ellen Marks Ambulatory Care Center

2013

Next-generation sequencing laboratory established

2014

Mark R. Neaman Center for Personalized Medicine established

2015

Program for Personalized Cancer Care (PPCC) established

2021

Kellogg Cancer Genomic Initiative (KCGI) launched

2023

Swedish Hospital Kellogg Cancer Center established

2024

Davis Family Center for Preventive Genomics established

Legacy of Excellence

What began as a small but innovative community cancer center has become a model for providing world-class cancer care close to home.

Since its founding in 1981 as the Kellogg Cancer Center at Evanston Hospital, the multidisciplinary team of clinicians has never deviated from the mission of patient-centric and community-connected excellence, leveraging state-of-the-art technology and dedicated subspecialty expertise to care for each individual patient.

Today, the Kellogg Cancer Center at the Endeavor Health Cancer Institute serves close to 5,000 new patients a year and about 20,000 unique total patients a year with a team of close to 200 clinicians including 40 physicians.

Our shared model of multidisciplinary, whole-patient care will offer pioneering cancer care to patients at all nine Endeavor Health hospitals, continuing a long-held tradition and culture of personalized and transformative care. This report covers the cancer programs at Endeavor Health Evanston, Glenbrook, Highland Park, Skokie and Swedish Hospitals.

91
Nurses/
Navigators

13
Advanced
Practice
Providers

5
Radiation
Oncologists

20
Pharmacists

4
Nutritionists

7
Social
Workers

9
Researchers

36
Oncologists

2,300+
Benign Hematology Patients/Year

5,000+
New Cancer Patients/Year

20,000+
Total Patient Visits



Noteworthy Retirements

Dr. Janardan Khandekar



CANCER CARE

Honoring a true pioneer

When Janardan Khandekar, MD, arrived at Evanston Hospital, there were just two rooms dedicated to cancer care, and the space had to serve both clinical and research needs.

The beloved physician led the development of a transformative cancer program, which has continued to focus on its early mission of providing the best possible care to patients in the most compassionate way.

“[Dr. Khandekar] transformed cancer care from a one-physician operation to the expansive, comprehensive subspecialty-based multidisciplinary program it is today — an academic-modeled cancer program in a community cancer center,” said Bruce Brockstein, MD, Medical Director, Endeavor Health Cancer Institute Kellogg Cancer Center. “Several key surgical colleagues were also pivotal contributors.”

The founding Head of the Division of Medical Oncology, Dr. Khandekar also served as the Chairman of the Department of Medicine and spearheaded the development of the personalized medicine program.

The impact of his leadership cannot be overstated.

Dr. Khandekar also helped shape the next generation of physicians by training more than 500 residents and many fellows. He sponsored oncology training for 12 physicians from India through a fellowship established in memory of his father. “He mentored countless of our current physicians and leaders in oncology and remains a great friend to us all,” added Dr. Brockstein.

From making house calls to taking a holistic approach to care for entire families, Dr. Khandekar touched the lives of thousands of patients and family members — and his compassion remains a touchstone for many.

Retired from medical oncology, Dr. Khandekar still has his hand in clinical medical genetics and lab and translational research in genomics to continue advancing care and saving lives, leveraging genomics for better prevention, detection and treatment options.

PATHOLOGY

Paying tribute to a visionary

A nationally recognized leader in pathology, specializing in molecular pathology and medicine, Karen Kaul, MD, PhD, was named Chair of the Department of Pathology and Laboratory Medicine in 2012.

Honored with countless awards, Dr. Kaul led the development of our advanced laboratory program.

From pharmacogenomics to genomic profiling of tumors with next-generation sequencing, the department has pushed the boundaries of advanced technology and expertise to drive patient benefits

and the critical evolution of personalized medicine at Endeavor Health.

Dr. Kaul was recognized in 2008 with an Innovation Award for development and implementation of the nation’s first MRSA admissions screening protocol. She was also named one of Crain’s 2020 Notable Health Care Heroes for leading the Lab Team in developing the first independent COVID-19 test in the State of Illinois.

Her groundbreaking accomplishments have created a legacy of state-of-the-art clinical laboratory testing committed to the fastest, most efficient and most accurate results. Dr. Kaul announced her plans to retire as Department Chair in 2026 but will continue to work with the department to help with the transition.

“Dr Kaul has had a remarkable career,” said Dr. Brockstein. “We’ve been extremely fortunate to have her leadership as a visionary in establishing one of the first molecular pathology laboratories in a community academic hospital. As Chair of Pathology, she has transformed the diagnostic care of cancer patients (and many others), allowing our patients to be served as they would or better than at a major academic medical center. She was also instrumental in many research projects and the establishment of our Molecular Tumor Board. Above all, she’s been a great colleague and friend to many, including me.”

Dr. Karen Kaul



SURGICAL ONCOLOGY

Recognizing many contributions, impactful career

After a long and impactful tenure, Mark Talamonti, MD, retired from his role as the NorthShore Chairman of Surgery.

A highly respected surgical oncologist, teacher and surgical leader, Dr. Talamonti began his role as Chairman of Surgery in 2007, following his recruitment from Northwestern Memorial Hospital where he was the first Division Chief of Surgical Oncology.

Under Dr. Talamonti's leadership, the Department of Surgery has grown to include more than 90 subspecialized surgeons recruited from many of the top programs in the country. Dr. Talamonti was instrumental in growing subspecialized clinical programs, ensuring the success of the Surgical Outcomes Research Program (SORP) and staunchly advocating for and

directly contributing to personalized cancer care.

His tenure included numerous awards and recognition for many of our surgical programs. Under Dr. Talamonti's leadership, the Department of Surgery tripled the number of open clinical trials and doubled external research funding. He supported the launch of new fellowship training programs in advanced minimally invasive surgery and breast surgery and served as a role-model educator, recognized with the Outstanding Faculty Teaching Award from the University of Chicago Pritzker School of Medicine 15 years in a row.



Dr. Mark Talamonti

Leadership Announcements

As Endeavor Health works to build a nationally recognized physician-led Medical Group model designed to be the best place for patients to receive care, expert clinicians were tapped to serve as Physician Executives.

Bruce Brockstein, MD, was named the new Endeavor Health Medical Group Physician Executive for Hematology/Oncology. The Director of Endeavor Health's Kellogg Cancer Center and a Clinical Professor of Medicine at the University of Chicago Pritzker School of Medicine, Dr. Brockstein has been a practicing medical oncologist since 1996, focused on the subspecialty areas of head and neck cancer, bone and soft tissue sarcoma, and melanoma, and a clinician at NorthShore/Endeavor Health since 1999.



Dr. Bruce Brockstein


Alla Gimelfarb, MD, has assumed the role of Division Head of Hematology/Oncology. She has served as Medical Director for Kellogg Cancer Center Immediate Care as well as the Coumadin Clinic. She also shared leadership responsibility for Evusheld triage and distribution during the COVID-19 pandemic.

Dr. Alla Gimelfarb



After a rigorous national search, Michael Ujiki, MD, was named NorthShore Hospitals Chair and Endeavor Health Physician Executive for Surgery. An accomplished surgeon, educator and innovator, Dr. Ujiki brings nearly two decades of leadership, clinical excellence and academic achievement to his new role. He's a nationally recognized expert in minimally invasive surgery and has held numerous leadership positions at Endeavor Health. He's also served as a Clinical Professor of Surgery at the University of Chicago Pritzker School of Medicine since 2009.

Dr. Michael Ujiki



Major Recruits

Clinical expertise

Ted James, MD, joined the team as the inaugural System Physician Executive of Endeavor Health Cancer Institute in May 2025.

Following a highly competitive national search, Dr. James was selected for his extensive clinical expertise and leadership. He most recently served as Chief of Breast Surgical Oncology and Director of the BreastCare Center at Beth Israel Deaconess Medical Center where he developed a National Institutes of Health (NIH)-funded research program. Dr. James was an Associate Professor of Surgery at Harvard Medical School and served in many leadership roles in healthcare initiatives while working as a healthcare executive coach and advocate for physician wellness.

"I was drawn to Endeavor Health's vision of transforming care for our communities and the opportunity to build on its strong cancer programs," said Dr. James. "My vision is for the Cancer Institute to lead in precision oncology, holistic care and the expansion of clinical trials that bring the best science to the communities we serve. We want to deliver care that not only meets today's needs but also helps shape the future of cancer care."



Dr. Ted James

Propelling innovation

Medical oncologist Mia Levy, MD, PhD, joined the team as Physician Director for Innovation for Hematology/Oncology in late 2025.

Dr. Levy will perform several roles in her new position, including continuing her clinical practice with breast cancer patients. Her Director for Innovation work will involve efforts to advance cancer molecular diagnostics and cancer bioinformatics as well as artificial intelligence (AI) use for cancer diagnosis and treatment.

Dr. Levy will help Endeavor Health stay ahead of new innovations in screening, diagnostics, therapeutics and survivorship. She has had an esteemed career as a pioneer and national leader in health informatics and molecular cancer diagnostics and cancer center administration. Dr. Levy was recruited from the Rush MD Anderson Cancer Center and most recently held the role of Chief Medical Officer at Foundation Medicine.

**“
We want to
deliver care that
not only meets
today’s needs
but also helps
shape the future
of cancer care.**

–Dr. Ted James
System Physician Executive of
Endeavor Health Cancer Institute

Advancing immunotherapy

After a lengthy national search, Dhruv Bansal, MD, MBA, was named the Program Director of Immunotherapy in June 2025 and will play an important role in further developing both clinical care delivery and research in this vital area. He’s a clinical thoracic/lung oncologist and will also see patients with malignant melanoma.

Before joining Endeavor Health, Dr. Bansal was an oncologist at Saint Luke’s Health System in Kansas City, Missouri, where he successfully developed and grew a thoracic/lung oncology program and clinical research infrastructure. He was on faculty at the University of Missouri-Kansas City. His new role will involve forging critical partnerships with multidisciplinary colleagues to ensure that the latest diagnostic, clinical and research therapeutic immunotherapy programs — including checkpoint inhibitors, bispecific antibodies and cell therapy — are in place and optimized to benefit patients.

Dr. Bansal will also work with thoracic medical oncology and thoracic surgery to develop clinical research, including thoracic oncology clinical trials and translational research efforts. “As Program Director of Immunotherapy, my goal is to lead the development of experimental and cellular therapeutics in thoracic and immuno-oncology,” said Dr. Bansal.



Improving Outcomes

HIPEC provides benefits for patients with advanced cancers

Led by gastrointestinal surgical oncologist Melissa Hogg, MD, MS, a new HIPEC (hyperthermic intraperitoneal chemotherapy) program provides the latest therapy for patients with advanced cancers, including appendiceal and colorectal cancer and mesothelioma.

Dr. Hogg's fellowship training includes experience in the more complex surgeries that can involve removal of multiple organs or tumors before pumping heated chemotherapy drugs into the abdomen. The program involves wide, multidisciplinary collaboration involving medical oncology, pharmacy, operating room, nursing staff and more. Development is in the works to expand the program to help treat ovarian and gastric cancer patients, a newer area of promise for the sophisticated treatment.

The pioneering therapy is particularly effective for certain cancers that are not chemotherapy-sensitive and are better treated with surgery and chemotherapy given regionally (within the abdominal cavity). Expertise is required to determine the specific biology and origin of the cancer to determine whether HIPEC is appropriate as not all patients are candidates for the procedure, stressed Dr. Hogg.

Some patients will respond more positively to receiving chemotherapy

before the HIPEC surgical procedure. Recent data has shown that HIPEC offers a high 10-year survival rate for patients with some cancers with extensive carcinomatosis, like appendiceal mucinous neoplasms. "People with aggressive and advanced cancers need the opportunity for hope," said Dr. Hogg. "It's very gratifying to have this treatment that does that."

National recognition for excellence in rectal cancer care

Among a select group of institutions in the country, Endeavor Health is accredited by the National Accreditation Program for Rectal Cancer (NAPRC) for delivering the highest standard of multidisciplinary care to patients with rectal cancer.

Developed by the American College of Surgeons and its Commission on Cancer in collaboration with the Consortium for Optimizing the Surgical Treatment of Rectal Cancer, the NAPRC establishes comprehensive, evidence-based standards that improve patient outcomes through structured, team-based care.

This prestigious accreditation reflects years of work by a multidisciplinary team of colorectal surgeons, radiologists, pathologists, oncologists, nurse navigators and administrative leaders. Accreditation required the creation of

“

This is about delivering better outcomes, with fewer complications, and higher quality of life for our patients.

*-Dr. Monika Krezalek
Director, Rectal Cancer Program*



rigorous protocols including formal multidisciplinary team conferences, standardized staging and pathology, patient-centered treatment planning, longitudinal follow-up, and the implementation of advanced protocols such as organ preservation strategies including "watch-and-wait," as well as integrated survivorship planning.

"Our NAPRC accreditation demonstrates our institution's commitment to not only meeting but exceeding the national benchmark for rectal cancer care," said Monika Krezalek, MD, Clinical Liaison Physician for the Commission on Cancer and Director of the NAPRC. "This is about delivering better outcomes, with fewer complications, and higher quality of life for our patients."

Recent national studies have confirmed the value of NAPRC standards in improving rectal cancer outcomes.

Advances in care — including the latest approaches in robotic and minimally invasive surgery for rectal cancers — are especially important as the number of colorectal cancer patients continues to grow, including a concerning rise in the number of younger patients.



Personalized Medicine

Davis Family Center for Preventive Genomics

Already a leader in using genomics to improve patient outcomes, Endeavor Health has advanced lab capabilities, industry-leading expertise, engaged physician leaders and strategic industry partners ready to fully integrate genomics into both primary care and superior cancer treatment.

A transformative philanthropic gift from William and Karen Davis to establish the new Davis Family Center for Preventive Genomics will now drive an expanded commitment to personalized medicine. The Center will provide patients with

more proactive information about their genomics, leading to better-informed decisions about early diagnosis, prevention and personalized treatment options. Clinicians will harness advanced genetic information to help fight later-stage disease.

The work of the Center will help mainstream genetic testing and streamline

the process for oncologists to order germline and pharmacogenomic testing before patients begin treatment, including chemotherapy. These innovations can help determine those at greatest risk for adverse side effects and help guide dosage, potentially reducing issues with toxicity.



William and Karen Davis

Cellular therapies program development

A leader in providing advanced immunotherapy treatments, Kellogg Cancer Center continues to expand its cellular therapy program and offerings.

CAR T-cell therapy has proved to be transformative for lymphoma patients like Natalie Mudrik, whose disease was not responsive to other treatments (see *her story on page 13*).

One of the first non-university-based certified CAR T-cell treatment programs in the state, the initiative is led by hematologist David Grinblatt, MD.

“Our dedicated in-house team is very nimble,” said Dr. Grinblatt, “and we’re able to get patients approved efficiently and get their cells quickly

so we can begin treatment as soon as possible.”

The program started with one agent for CAR T-cell treatments, and it now has five different agents approved for different conditions, with more on the horizon. Cellular therapies are now offered for most blood cancers, including lymphoma, myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Plans are in the works to offer tumor-infiltrating lymphocyte therapy for solid tumors at Endeavor Health to ensure we maintain the latest cancer-fighting protocols. “This advanced technology broadens our opportunities for when standard therapies are not working,” added Dr. Grinblatt. “I’ve watched this technology develop over 25 years, and it’s wonderful to see it help patients in my care.”


Blood test for early detection

The promise of detecting cancer with a simple blood test, and early enough to start treatment when it’s most effective, could become a reality thanks to Exact Sciences’ Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) Study and Endeavor Health’s participation.

Together with other study sites, Endeavor Health will enroll up to 25,000 participants in a study spanning a five-year period. During this time, the Falcon study will assess the clinical performance of MCED testing, as well as patient and provider experiences with MCED testing.

The MCED test analyzes both DNA and proteins to flag changes that may be suggestive of cancer. The only MCED test available today using a multi-biomarker class approach, the test can help clinicians identify many types of cancers, including those not currently detected through standard screening methods.

The study will create a registry that tracks patient data over time to evaluate outcomes, understand the influence of MCED testing on patient care, and guide improvements in future strategies for cancer screening and treatment.



Drs. David Grinblatt and Lynne Kaminer

“Our dedicated in-house team is very nimble, and we’re able to get patients approved efficiently and get their cells quickly so we can begin treatment as soon as possible.”

-Dr. David Grinblatt
Medical Lead, Cellular Therapy



Thriving Patients

Advanced immunotherapy leads to centenarian celebration

A World War II veteran, Sir Emil Hirsch survived the Battle of the Bulge and countless other challenges. He was not about to let skin cancer rob him of reaching his 100th birthday.



In early 2025, 99-year-old Hirsch was referred to oncologist Bruce Brockstein, MD, with a large squamous cell cancer on the left side of his forehead and scalp. He had been treated with surgery and radiation for earlier skin cancers in the same spot on his head, and unfortunately the cancerous lesion was now very large, massively ulcerated and infected.

“They couldn’t radiate it any more, and the cancer was down to the bone,” said Hirsch, who was delighted to learn that Dr. Brockstein had something else to offer him in the form of an advanced immunotherapy medication.

“Most squamous cell cancers are fairly easy to treat with surgery and they don’t come back — but they can, as in this case, be very aggressive,”

explained Dr. Brockstein, who got Hirsch started with immunotherapy infusions.

Almost immediately, the lesion began healing and Hirsch had little to no problems tolerating the treatment he received every third week at Endeavor Health Highland Park Hospital.

“He’s gotten the best of both worlds in terms of great responsiveness to the therapy and no real side effects,” said Dr. Brockstein, “and he likely wouldn’t be alive now without these drugs.”

The American-born Hirsch — who in 2023 was appointed a Knight in the French Legion of Honor, the country’s highest military distinction, for helping to liberate France from Nazi occupation — has a lifetime of accomplishments reflected by numerous military awards and civic, business and religious engagement roles and rewards.

“You have to be alive to receive the French Legion award,” Hirsch said with a smile.

From a career in publishing and editing to founding the Highland Park Pops Big Band, Hirsch’s interests are varied and vast, and he shows no signs of slowing down. He’s helped compile links to thousands of pieces of music for sing-alongs at his senior living community and records academic books using his own studio equipment so they’re available for his daughter who has vision challenges. A great storyteller, Hirsch’s memory for dates, times, places and myriad details is enviable.

Asked about his secret to longevity, Hirsch admits he has no idea.

“I don’t linger in the past, and age has never been one of the goals,” said Hirsch. “I deal with whatever is in front of me in the moment, taking care of the problems or activities of the day.”

“It’s rewarding to have a patient like this who has seen so much and still is so vibrant,” said Dr. Brockstein. “I’m looking forward to spending more time with his second century.”

CAR T-cell therapy offers new hope

Natalie Mudrik began experiencing neck pain and increasing shortness of breath and then noticed a lump on her neck. Initially, she dismissed the symptoms — but at the urging of concerned friends, she eventually sought medical attention.

At age 45, Mudrik was diagnosed with an aggressive form of non-Hodgkin lymphoma, with tumors located in her neck, chest and abdomen. Having no primary care physician at the time, she was referred to hematologist David Grinblatt, MD, by Bruce Brockstein, MD, who was caring for Mudrik’s father as he battled metastatic melanoma.

“Dr. Brockstein and Dr. Grinblatt are among the kindest and most compassionate physicians I’ve ever met,” said Mudrik. “Their approach to care is truly exceptional, and I believe other doctors could learn a great deal from the way they connect with and support their patients.”

By the time of her first appointment with Dr. Grinblatt, Mudrik’s breathing was very labored. She was immediately admitted to the hospital and began treatment, which included six rounds of IV infusion chemotherapy every three weeks.

After the first few rounds of chemo, the tumors in her chest had shrunk, her

breathing was better, and both Mudrik and Dr. Grinblatt were hopeful. The scan after the final round of chemo showed her cancer was in remission. Unfortunately, the remission lasted just two months, and the cancer returned and spread to her brain.

“While her kind of cancer usually responds well to chemotherapy, her disease was very advanced,” said Dr. Grinblatt, who knew that CAR T-cell therapy — a pioneering immunotherapy that offers new hope for patients like Mudrik — was the next step.

Mudrik underwent eight additional rounds of chemotherapy to help shrink the tumors in her brain before receiving her CAR T-cell infusion. Her own immune cells were collected, genetically engineered to target the cancer and then infused back into her body. While many patients face intense side effects from this advanced therapy, Mudrik shared that her earlier rounds of chemotherapy were actually more difficult. Through it all, she remained

unwavering — placing her trust in her care team and moving forward with the steadfast belief that she would overcome her cancer.

“In my mind, getting through this was the only option,” Mudrik said. “With Dr. Grinblatt in my corner, his knowledge and experience made me feel that I was in great hands.” Her CAR T-cell therapy included a two-week hospital stay, during which time she formed close bonds with the incredible nurses and the entire care team at Endeavor Health Evanston Hospital.

“Her positive attitude really helped her get through and deal with the treatment and the effects of her cancer,” said Dr. Grinblatt.

Mudrik is now approaching the one-year mark following her CAR T-cell therapy, and her scans continue to look good. “It’s been rough in a lot of ways, but I’m finally beginning to feel like myself again,” she said. “I’m a big believer in science and doctors, and I feel extremely fortunate that CAR T-cell therapy was an option for me and that I had an amazing doctor and care team.”

For now, she’s looking forward to traveling with friends and enjoying life to the fullest from walks with her dog to baseball games with her nephews and doing things she hasn’t been able to do the past few years.

Drs. Allison DePersia, Catherine Pesce, Carol Rosenberg and Poornima Saha



Multidisciplinary Breast Cancer Program

Personalized approach to screening, diagnosis and treatment

Breast cancer affects millions of women in the United States. According to the American Cancer Society, breast cancer accounts for about 30% of all new female cancers each year, and women have a 1-in-8 chance of developing breast cancer over the course of their lives. Rates of breast cancer are climbing, and those numbers are increasing more sharply in women under age 50.

Our collaborative, experienced team of specialists works to identify patients at high risk, offer personalized screening recommendations, leverage advanced imaging for early and more accurate diagnosis, and focus on individualized treatment plans.

The first center in Chicago to be accredited by the National Accreditation Program for Breast Centers (in 2009), the Endeavor Health

Cancer Institute Kellogg Cancer Center breast cancer program is now one of the largest breast-care programs in the state.

Patients who are identified for high-risk evaluation — by either their primary care physician, gynecologist or radiologist — at the time of a breast cancer screening are referred to our High-Risk Breast Clinic where family history and genetic testing are discussed.

“While traditional genetic testing is still our standard of care for identifying individuals at high risk for breast cancer and other cancers, there are also many other factors that contribute to cancer risk,” said medical oncologist Allison DePersia, MD. “Even with a negative genetic test, increased cancer screening may be recommended, and it’s important that patients make lifestyle changes to reduce their cancer risk.”

Advanced diagnostics — including 3D mammography, automated breast ultrasound screening (ABUS) and breast MRI — are used to better diagnose breast cancer, particularly for women with dense breast tissue.

New breast cancer cases are presented to the tumor board, bringing multidisciplinary specialists together to ensure optimal treatment plans and improved outcomes.

Patients requiring surgical treatment have access to fellowship-trained surgeons experienced in pioneering treatments including nipple-sparing mastectomy and oncoplastic breast surgery, designed to leave breasts looking as natural as possible after treatment. Endeavor Health is now a national leader in oncoplastic surgery, and Katherine Kopkash, MD, leads American Society of Breast Surgeons training in the field.

Research Highlights

Optimizing genomics-guided care

Rapid advances in molecular and cell biology have led to a paradigm shift in cancer management. Next-generation sequencing (NGS) technologies have significantly advanced the field of tumor genetics. It's now possible to use NGS to identify precise genomic markers within the tumor, which allows for the use of targeted therapies.

By sequencing vast regions of the genome at unprecedented speed and accuracy, NGS can identify a wide range of genetic alterations, including mutations, copy number variations and fusions that can drive tumor growth and progression. This information can dramatically impact diagnosis and treatment and provide better prognostic information.

Building upon the strong reputation of the Department of Pathology and Laboratory Medicine and its state-of-the-art molecular diagnostics laboratory, Kellogg Cancer Center received pilot funding from the Mark R. Neaman Center for Personalized Medicine's Transformation Through Innovation Fund to support a research project to incorporate genomic testing and pharmacogenomics for patients diagnosed with advanced cancer.

The Kellogg Cancer Genomic Initiative (KCGI), led by Karen Kaul, MD, and Bruce Brockstein, MD — along with a multidisciplinary team from pathology, bioinformatics, pharmacy, health information technology, oncology and medical genetics — used in-house NGS to characterize the tumor mutations of patients with

advanced or metastatic cancer.

Enrollment in this prospective, observational research project began in 2021 and involved 251 patients who had NGS on tumor tissue. This in-house molecular pathology testing includes an expanded NGS panel reporting 158 genes with secondary broader analysis to evaluate tumor mutation burden and a smaller panel of 50 genes for limited samples, and a 10-gene fusion panel. The testing enables our laboratory to keep up with the increasing number of targeted therapeutics available in recent years.

As part of the study, 54.2% of patients with advanced cancers were identified as candidates for FDA-approved therapies (either approved or off label), reinforcing the benefits of genomics-guided care for cancer patients.

The KCGI project led to the development of a genomics-guided care model leveraging Endeavor Health's in-house molecular diagnostics, bioinformatics, personalized medicine and a multidisciplinary Molecular Tumor Board in a sustainable workflow supporting precision oncology.

A manuscript has been accepted for publication in *Cancers*.

Driving early detection with increased lung cancer screening

Despite having been proven to reduce the risk of dying from lung cancer, lung cancer screening with low-dose computed tomography remains significantly underutilized.

Current guidelines recommend annual screening for individuals who currently smoke and those who have quit within the past 15 years and who have at least a 20 pack-year history of smoking. (A pack year equals smoking one pack per day for a year, smoking two packs a day counts as two pack years and so on.) Unfortunately, nationally fewer than 20% of patients who are eligible for lung cancer screening actually get scanned, while many patients who develop lung cancer are not eligible for screening under current guidelines.

A recent study led by Seth Krantz, MD, Division Head of Thoracic Surgery and Chairman of the NorthShore Cancer Committee, looked at how polygenic risk scores (PGSs) interact with smoking history as they relate to individual risk of developing lung cancer and whether they could be used to better identify patients at higher risk of developing the often-deadly disease.

Data from the Endeavor Health Genomic Health Initiative (GHI), where participants underwent whole-genome sequencing, was used in the analysis. Lung cancer prevalence increased significantly with higher PGS risk, and PGSs provided meaningful risk



Dr. Jianfeng Xu

stratification among smokers.

While smoking remains the largest single risk factor for developing lung cancer, a patient's PGS was shown to provide additional risk stratification detail and may help identify those at greatest risk, paving the way for targeted interventions and screening recommendations.

Working in partnership with Jianfeng Xu, MD, DrPH, MPH, and the Mark R. Neaman Center for Personalized Medicine, the study represents an important effort in better understanding inherited risk factors with the aim of ensuring lung cancer screening guidelines include those at greatest risk.

The study was presented at the 2025 American Association for Thoracic Surgery International Thoracic Surgical Oncology Summit in Boston and has been submitted for publication.

"We're looking to partner with colleagues here and potentially at other institutions to continue to better identify those who would most benefit from screening," said Dr. Krantz, who is also involved in other collaborative studies to identify novel genes associated with lung cancer.

Training the next generation of hematology/oncology physicians

The first class of the Hematology/Oncology Fellowship Program of the University of Chicago Endeavor Health–NorthShore Hospitals Program will begin their training in the summer of 2026.

Recruitment drew 375 applicants for two positions and the top two candidates were selected in December, 2025—Courtney Sanchez, MD, and Melissa Gunchenko, MD. The three-year fellowship is sponsored by the University of Chicago Pritzker School of Medicine and gives fellows access to a range of first-rate learning and career growth opportunities. The three-year fellowship is sponsored by the University of Chicago Pritzker School of Medicine and gives fellows access to a range of first-rate learning and career growth opportunities.

Directed by medical oncologist Teresa Murray Law, MD, and Associate Program Director medical oncologist Ami Badami, MD, the program features faculty leadership who are deeply invested in training the next generation of clinicians. "We see ourselves as educators along with being active clinicians," said Dr. Law. Clinical rotations by University of Chicago fellows have been well-received since 2010, and the new dedicated fellowship is a natural next step. "We know that when you're an educator, you're a better learner yourself," she added, "and we believe it's important to be part of educating future physician leaders."

Faculty includes 25 hematology/oncology disease-specific subspecialists in both benign and malignant hematology and solid tumor oncology (breast, gastrointestinal, thoracic, head and neck, genitourinary, gynecologic oncology, neuro-oncology, cutaneous and sarcoma). The program incorporates additional training in medical genetics, radiation oncology, surgical oncology, molecular pathology, pharmacology/chemotherapy, blood banking and palliative care.

Fellows will spend time at the Kellogg Cancer Centers at Endeavor Health Evanston and Glenbrook Hospitals as well as inpatient care at Evanston Hospital. Allogenic bone marrow transplant training takes place at the University of Chicago Medical Center. Fellows will also have dedicated time to pursue research opportunities in the second and third years of the program.

The mission of the fellowship is to inspire and empower a diverse group of fellows through rigorous training and compassionate care to become outstanding clinicians and visionary leaders and innovators in hematology/oncology.



Dr. Melissa Gunchenko



Dr. Courtney Sanchez

Dr. Carol A. Rosenberg



Survivorship redefined in nationally recognized MRW LIFE Program

While more people than ever are surviving cancer, survival alone is no longer the only goal.

Life after treatment often brings a new set of challenges including fatigue, anxiety, fear of recurrence, lingering side effects and questions of identity.

The Myra Rubenstein Weis (MRW) Living in the Future (LIFE) Cancer Survivorship Program directed by Carol A. Rosenberg, MD, provides a precision model of survivorship care personally tailored to each individual. The program integrates clinical support, research-informed care and survivor-driven education to support “living in the future.”

Beginning with a personalized clinic visit with an oncology advanced practice nurse, survivors receive prescriptive guidance for reconnecting

to life while staying linked to essential oncology care. The personalized care plan includes everything from long-term surveillance and follow-up recommendations to lifestyle and wellness recommendations, preventive care tools, and referrals to consultative survivorship specialists.

Evenings of Survivorship workshops address key concerns from the survivor community, including nutrition, emotional wellbeing, fitness, cognition, intimacy and more. Informed by a robust, ongoing survivor-reported outcomes database, the MRW LIFE Program is refined based on regular feedback — 70% of survivors report significant worries from fear of recurrence to changes in sexual health.

In addition to empowering and informing survivors, the MRW LIFE Program also strives to transform the future of healthcare by training clinicians through a CME-accredited LIFE Cancer Survivorship course.

Nationally recognized by the Commission on Cancer and the National Accreditation Program for Breast Centers, the MRW LIFE Program helps restore health, hope and futures for survivors navigating their lives beyond cancer.

Essential Charitable Support

Philanthropy has been the driving force for much of Kellogg Cancer Center's enormous success these past 40 plus years.

From its most innovative approach to care to its overall personalized support of patients beyond the latest treatments and novel clinical trials, Kellogg Cancer Center and Endeavor Health has and continues to treat the whole person as well as the cancer itself from a molecular level. Not only do patients receive the latest, most targeted treatment, the gentler side of medicine also is front and center. Contributions, at any level, go a long way toward ensuring all have access to the best care possible – right in their own backyard no matter the ability to pay.

Our culture and commitment to quality and providing compassionate care is unmatched. Kellogg Cancer Center Endeavor Health is leading the charge in leveraging the power of genetics and stopping cancer in its tracks before it takes hold. For those with more advanced disease, genetic testing also has increased survival as it enables our talented oncologist and hematologists to see genetic mutations and tumor site changes in real time. This takes the guess-work out of the next steps and arms physicians with the power to get out in front of disease or pivot at the right time with other

proven cancer-fighting strategies. Donor dollars are integral to delivering the expert care every patient deserves.

These are exciting times at Kellogg Cancer Center and the Endeavor Cancer Institute. Several new staff and nationally recognized clinical leaders have joined forces with an experienced, dedicated team to take our program to the next level. We are optimistic about the future and are confident a cure is around the corner, or at least cancer will become a more manageable, chronic disease. The science is moving so fast and we remain poised to embrace what's next as well as drive new discoveries. Thank you for your consideration in joining forces with us as we strive to deliver world-class, local care. Your investment in Kellogg Cancer Center is an investment in us all.

To learn more about how you can support Kellogg Cancer Center, please call Kevin Gray in the NorthShore Endeavor Health Foundation at **224.364.7609** or visit **foundation.northshore.org**



Endeavor Health Cancer Institute

Academic Leadership Roles and Awards

Sameer Alvi, MD

- Section Head, Head & Neck Oncologic Surgery

Awards:

- NorthShore Faculty Resident Teaching Award

Tariq Azam, MD

- Director of Cardio-Oncology
- Member, Cardio-Oncology Section Leadership Council, American College of Cardiology 2022–2025
- Member, Chicago City-Wide Cardio-Oncology Rounds 2024–Present

Dhruv Bansal, MD

- Program Director for Immunotherapy, Kellogg Cancer Center
- Lead, Molecular Tumor Board, Kellogg Cancer Center
- Academic Lead for Thoracic Medical Oncology
- Volunteer Auditor, Alliance for Clinical Trials in Oncology
- Panelist, ACCC Precision Medicine Summit

Bruce Brockstein, MD

- Section Editor and Author, UpToDate — Head and Neck Cancer
- Physician Executive, Endeavor Health Medical Group — Hematology/Oncology
- Director, Endeavor Health Cancer Institute Kellogg Cancer Center

Robert Eisner, DO

Committees:

- American Society of Hematology Committee on Practice
- Subcommittee on Guideline Dissemination

Alla Gimelfarb, MD

- Division Head of Hematology/Oncology

Brian Helfand, MD, PhD

- Division Head, Urology
- Ronald L. Chez Family and Richard Melman Family Chair of Prostate Cancer
- Clinical Professor, University of Chicago Pritzker School of Medicine
- American Society of Cell Biology Keynote Address, “Novel Mechanisms of Intermediate Filament Transport,” August 2025

Awards:

- Leadership Award: Associate Chief Scientific Officer

Melissa Hogg, MD, MS

Awards:

- Inducted American Surgical Associations

National Committees:

- ACS (American Cancer Society)
 - 2023–Present: Cancer Surgical Standards Program
- AHPBA (Americas Hepato-Pancreato-Biliary Association)
 - 2020–Present: Executive Council
- SSO (Society of Surgical Oncology)
 - Board of Directors 2023–Present

Editorial:

- *Journal of Surgical Oncology*
 - 2015–Present: Associate Editor, Surgical Technique Division
 - 2024–Present: Associate Editor, Pancreas

Peter Hulick, MD, MMSc

- Division Head, Medical Genetics
- Medical Director, Mark R. Neaman Center for Personalized Medicine
- American Board of Medical Genetics and Genomics (ABMGG), Chair-Elect
- UpToDate topic author: “Basic genetics concepts: DNA regulation and gene expression”

- UpToDate topic author: “Principles and clinical applications of next-generation DNA sequencing”

Amanda Silver Karcioglu, MD

- Section Head, Endocrine Surgery
- American Academy of Otolaryngology-Head and Neck Surgery — Endocrine Surgery Committee
- American Head and Neck Society (AHNS) — Scientific Program/Resident Courses Service
- American Thyroid Association (ATA) — History and Archives Committee
- North American Society for Interventional Thyroidology (NASIT) — Patient Education Website Task Force

Awards:

- 2024 Honor Award — American Academy of Otolaryngology-Head and Neck Surgery

Editorial:

- Peer Review: *Thyroid; Endocrine Reviews; JAMA Otolaryngology-Head & Neck Surgery; Head & Neck; The Laryngoscope; Gland Surgery; Annals of Otolaryngology, Rhinology & Laryngology; Ear, Nose and Throat Journal; Frontiers in Oncology; Journal of the American College of Surgeons*

Kate Kopkash, MD

- Director of Oncoplastic Surgery
- American Society of Breast Surgeons Oncoplastic Surgery Task Force (Chair, 2024)
- Chicago Surgical Society (Vice President, 2023–2024)

Media:

- *General Surgery News*, December 2024, Vol 51 Num 10. “Steps to Improve Ergonomics in the OR, and Lengthen Your Career.”

Awards:

- Annals of Breast Surgery Most Read Paper Award for “The Surgeon’s Guide to Fibroadenomas” (Kopkash, Yao), 2025
- *Sheridan Road Magazine* Power Women, 2024
- Castle Connolly Top Doctor, 2024
- *Chicago* magazine Top Doctor, 2024
- ScholarGPS Top Scholar, 2019-2024

Seth Krantz, MD

- Chairman, NorthShore Cancer Committee
- Division Head, Thoracic Surgery, Endeavor Health Department of Surgery
- Clinical Associate Professor of Surgery, University of Chicago Pritzker School of Medicine

National Committee Membership:

- Standards Investigation and Validation Committee, American College of Surgeons Cancer Research Program
- Evidence-Based Surgery Writing Group, Sublobar Resection for Lung Cancer, Society of Thoracic Surgeons
- Health Policy and Advocacy Task Force, Society of Thoracic Surgeons

Awards:

- Excellence in Teaching, University of Chicago Department of Surgery

Monika Krezalek, MD

- Director, Rectal Cancer Program, Endeavor Health
- Cancer Liaison Physician, NorthShore Cancer Committee

Teresa Law, MD

- Program Director, University of Chicago Endeavor Health (NorthShore) Hematology/Oncology fellowship

Mia Levy, MD, PhD

- Director for Innovation, Hematology/Oncology

Ross Levy, MD**Awards:**

- America’s Leading Doctors 2025, *Newsweek* and *Statista*

Gregg Menaker, MD**Awards:**

- America’s Leading Doctors 2025, *Newsweek* and *Statista*

Douglas Merkel, MD

- Co-Chair, Endeavor Health NorthShore Institutional Review Board

Catherine Pesce, MD

- Division Head, Surgical Oncology

Awards:

- 2025: Clinical Professor, University of Chicago Pritzker School of Medicine
- 2025: Honoree, Myra Rubenstein Weis Executive Committee 28th Annual Benefit Luncheon, Highland Park, IL
- 2024: David P. Winchester, MD, Endowed Chair of Surgical Oncology
- 2024: Excellence in Teaching Award from the University of Chicago Department of Surgery for 2023-2024

Gustavo Rodriguez, MD

- Division Head, Gynecologic Oncology, Endeavor Health
- Top Doctors 2024, *Chicago* magazine
- 2025 Duke University School of Medicine: Andrew Berchuck, MD, Gynecologic Oncology Endowed Lecture: “Development of an Effective Pharmacologic Approach for the Chemoprevention of Ovarian Cancer”

Poornima Saha MD

- Panelist, 2025 28th Annual Myra Rubenstein Weis Health Resource Center Luncheon
- Early Investigator Career Development Program

Daniel Shevrin, MD

- Medical Director, Glenbrook Kellogg Cancer Center

Leslie Mendoza Temple, MD

- Chair, Medical Cannabis Advisory Board for the Illinois Department of Public Health, second term, appointed by Governor J.B. Pritzker
- Oversight Committee Co-Chair: 2024 International Research Congress for Integrative Medicine & Health, Seattle, Washington

Awards:

- *Chicago* magazine Top Doctors, cover story: “What’s Inside Top Doctors’ Medicine Cabinets?” December 17, 2024

Lauren Wiebe, MD

- Interim Director of Gastrointestinal Medical Oncology

Lectures:

- University of Chicago/Coleman National Training Program for APNs 2024-5 “Oncology for Palliative Care Providers”

Peer Review:

- *Journal of Oncology Practice*, 2025
- *Supportive Care in Cancer*, 2024

Weidong Xu, PhD

- Member, American Association for Cancer Research, The Association for Cancer Immunotherapy, NIH Center for Scientific Review Special Emphasis Panel Editorial: Cancer Gene Therapy Editorial Board

Katharine Yao, MD

- Vice Chair, Research and Development, Department of Surgery, Endeavor Health
- Director, Breast Cancer Research Department of Surgery

National Leadership:

- Chair, NAPBC
- Commission on Cancer breast disease site, Co-Lead for Quality Measures
- Chair, Benign Breast Disease Steering Group, The American Society of Breast Surgeons

Membership:

- Member, ASCO Germline Testing in Patients with Breast Cancer: ASCO-Society of Surgical Oncology Guideline Group
- 2024 American Surgical Society, member
- Agency for Healthcare Research 2025 Member, Quality Indicators (QIs) Diagnostic Safety Measures Expert Workgroup

Editorial:

- Editorial Boards: *Annals of Surgical Oncology*, *Annals of Breast Surgery*, *Journal of Surgical Oncology*

Awards:

- 2025 Distinguished Reviewer, JAMA Network Open Access
- JAMA Network Open Top Reviewer Recognition

Clinical Trials

For more information about clinical trials, visit endeavorhealth.org/services/cancer-institute/clinical-trials-research

Oncology Trials

Breast Cancer

EA1181 Compass (HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

A011801 The CompassHER2 trials (COMprehensive use of Pathologic response ASSESSment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib (closed in 2025)

S2007 A Phase II Trial of Sacituzumab Govitecan (IMMU-132) for Patients with HER2-Negative Breast Cancer and Brain Metastases (closed in 2025)

CCTG MA.39: Tailor RT A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

AFT-65/ASCENT-05/OptimICE-RD: GS-US-595-6184 A Randomized, Open-Label, Phase III Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

S2212 Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET)

A012103 OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Protocol NRG-BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)

NRG-CC011 Cognitive Training for Cancer-Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center, Randomized Double-Blinded Controlled Trial

Gastrointestinal Cancer

NRG-GI004/SWOG-S1610 COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab

Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

UC14-0594 Perioperative FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

S2303 Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Genitourinary Cancer

NRG-GU008 A Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)

S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High-Risk Prostate Cancer with Germline BRCA1/2 Mutations

NCI 000048 A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer

A032103-MODERN An Integrated Phase II/III and Phase III Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer

UC22-1318 A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients with High-Risk Localized Prostate Cancer

Gynecologic Cancer

AGCT1531 A Phase III Study of Active Surveillance for Low-Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard-Risk Pediatric and Adult Patients with Germ Cell Tumors

NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCK)

NRG-GY022 Assessment of carboplatin clearance predictors: A PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin

NRG-GY026 A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

VLS-1488-2201 A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer

EH22-383 A Randomized, Controlled Study of a Fasting Mimicking Diet (FMD) in Conjunction with Combination Carboplatin and Paclitaxel in the Treatment of Patients with Advanced or Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

EAY191-N4 A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

EAY191-N5 A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors

GOG 3097/Verastem VS6766-301 A Phase III, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

GOG 3095/MK2870-005/ENGOT-en23 A Phase III, Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

GOG 3088 A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma

GOG-3083/XPORT-EC-042 A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

VLS-1488-2201 A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer

Head and Neck Cancers

HCN Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

RTOG 1216 Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

A092105 Randomized, Phase II Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

EA3211 Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Hematology

CIBMTR Research database for hematopoietic stem cell transplantation, other cellular therapies and marrow toxic injuries

A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)

EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

EA9181 A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults

S1918 A Phase II/III randomized study of R-miniCHOP with or without CC-486 (oral azacitidine) in patients age 75 years or older with newly diagnosed diffuse large B-cell lymphoma, Grade IIIb follicular lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (NCT04799275)

EH23-066 A Pilot Study Assessing Neurocognitive Impairments in Adult Survivors of Adolescent and Young Adult Hematologic Malignancies

Novartis CVAY736O12301 A Phase III, Randomized, Double-Blind Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment (VAYHIA)

GO44145 A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma

MyeloMATCH Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials

MM1YA-S01 A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) Versus (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH: A myeloMATCH Clinical Trial

MM1YA-CTG01 A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax plus Chemotherapy for Newly Diagnosed Younger Patients

with Intermediate Risk Acute Myeloid Leukemia (AML): A Tier 1 MyeloMATCH Clinical Trial

JCAR017-EAP-001 Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release

MM10A-EA02 A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

Janssen 68284528MMY4006 Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (cilta-cel) Out-of-Specification (OOS) in Patients with Multiple Myeloma United States EAP

Lung Cancer

Lung-MAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer

A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)

AstraZeneca D926TC00001 A Phase III, Randomised, Open-Label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants with Stage I Adenocarcinoma Non-Small Cell Lung Cancer Who Are ctDNA-positive or Have High-Risk Pathological Features (TROPION-Lung12)

Neuro-Oncology

NRG BN003 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

A072201 Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade Versus SOC in Patients with Recurrent Glioblastoma

Skin Cancer

EA6141 Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Regeneron R3767-ONC-2208 A Phase II and Phase III Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD-1 Alone in Patients with Resectable Stage III and IV Melanoma

Other

Carevive OPT-IN® Real-World Treatment Experience of Patients with Breast, Lung, Multiple Myeloma, Acute Myelogenous Leukemia or Ovarian Cancer Using Remote Symptom Monitoring

A151804 Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Genomic Panels Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer

ANTHOS 8 A multicenter, randomized, open-label, blinded endpoint evaluation, phase III study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Anthos 7 A multicenter, randomized, open-label, blinded endpoint evaluation, phase III study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

EAY191 Molecular Analysis for Combination Therapy Choice (ComboMATCH)

NCI 10323 Cancer Moonshot Biobank Research Protocol

EH12-382 Comprehensive Biosample Collection (CBC)

Surgical Trials

Breast Cancer

EH22-349C BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase III Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation

EH23-039 A Prospective, Multicenter Randomized Controlled Trial (RCT) of the da Vinci® SP™ Surgical System Versus Open Surgery in Nipple-Sparing Mastectomy (NSM) Procedures

EH20-166 The ergonomic effects of the robotic nipple-sparing mastectomy on the operating surgeon

EH22-492 Patient Quality of Recovery After PECS Blocks with Liposomal Bupivacaine at 72 Hours Postoperatively from Mastectomy

EH15-297 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

EH17-072 Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Trial for Low-Risk DCIS: A Phase III Prospective Randomized Trial

Gastrointestinal Cancer

EH12-468 PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery



Research Publications 2025

Aggarwal R, Heller G, Hillman DW, Xiao H, **Shevrin D**, et al. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Pts with High-Risk Biochemically Relapsed CSPC (AFT-19). *J Clin Oncol*. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. PMID: 38261983

Allen ML, Pastor A, Leslie K, Fitzpatrick B, **Hogg M**, Lau H, Manski-Nankervis JA. Patient experience of discharge opioid analgesia and care provision following spine surgery: A mixed methods study. *Br J Pain*. 2025 Feb 19;20494637251322168. doi: 10.1177/20494637251322168. Online ahead of print. PMID: 39990194

Allen PB, Bazzi L, Zhang B, Chen Q, Slonim LB, Savas H, Advani RH, Evens AM, Pro B, Karmali R, Mou E, **Eisner R**, Bayer R, Gordon LI, Winter JN. Extended Follow-Up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed by AVD Chemotherapy. *Blood* (2024) 144 (Supplement 1): 1664

Armstrong M, Lu P, Wang J, El-Hayek K, Cleary S, Asbun H, Alseidi A, Tran Cao HS, Wei AC; SAGES HPB Committee (**Hogg M**). Advancing minimally invasive hepato-pancreato-biliary surgery: Barriers to adoption and equitable access. *Surg Endosc*. 2024 Aug 8. doi: 10.1007/s00464-024-11078-1. Online ahead of print. PMID: 39117957

Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, **Helfand BT**, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballesterio EP, Cleaver R, Varughese M, Barwell J, LeButt M,

Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles RA, Aaronson NK. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. *BJU Int*. 2024 Sep;134(3):484-500. doi: 10.1111/bju.16432. Epub 2024 Jun 5. PMID: 38839570

Bansal D. Immune-related adverse events, survival outcomes, and next steps in stage III melanoma: Real-world experience at an NCI comprehensive cancer center. *Oncologist*. October 2025

Bansal D. Immunotherapy Response and Survival Outcome by Immunophenotypic Signature in Non-Small Cell Lung Cancer. Hawaii Lung Global Summit. June 26, 2025, Oral Presentation

Bansal D. Immunotherapy: Side Effects and Management. Vumedi. October 16, 2025, Oral Presentation

Bansal D. Neoadjuvant and Perioperative Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer. Hawaii Lung Global Summit. June 25, 2025, Oral Presentation

Bansal D. Treating Unresectable Stage III NSCLC. Updates in Thoracic Oncology from the Masters. September 27, 2025, Oral Presentation

Barreto SG, Strobel O, Salvia R, Marchegiani G, Wolfgang CL, Werner J, Ferrone CR, Abu Hilal M, Boggi U, Butturini G, Falconi M, Fernandez-Del Castillo C, Friess H, Fusai GK, Halloran CM, **Hogg M**, Jang JY, Kleeff J, Lillemoen KD, Miao Y, Nagakawa Y, Nakamura M, Probst P, Satoi S, Siriwardena AK, Vollmer CM, Zureikat A, Zyromski NJ,

Asbun HJ, Dervenis C, Neoptolemos JP, Büchler MW, Hackert T, Besselink MG, Shrikhande SV; International Study Group for Pancreatic Surgery. Complexity and Experience Grading to Guide Patient Selection for Minimally-Invasive Pancreatoduodenectomy: An ISGPS Consensus. *Ann Surg*. 2024 Jul 22. doi: 10.1097/SLA.0000000000006454. Online ahead of print. PMID: 39034920

Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, Kohlman WK, Kurian AW, Laronga C, Lynce F, Norquist BS, Plichta JK, Rodriguez P, Shah PD, Tischkowitz M, Wood M, Yadav S, **Yao K**, Robson ME. Germline Testing in Patients with Breast Cancer: ASCO–Society of Surgical Oncology Guideline. *J Clin Oncol*. 2024 Feb 10;42(5):584-604

Bello A, Alikhan MB, Subramaniam A, Yusuf ZI, **Brockstein B**, Ravi V. Adult-onset multifocal kaposiform hemangioendothelioma in the bone marrow, lung, liver, and brain: A case report. *Front Oncol*. 2024 Feb 22;14:1322684. doi: 10.3389/fonc.2024.1322684. eCollection 2024. PMID: 38454925

Billings LK, Shi Z, Mulford AJ, Wei J, Tran H, Ashworth A, Zheng SL, **Dunnenberger HM**, **Hulick PJ**, Sanders AR, Xu J. Validation of GenProb-T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system. *J Diabetes Investig*. 2024 Aug 22

Billings LK, Shi Z, Mulford AJ, Wei J, Tran H, Ashworth A, Zheng SL, **Dunnenberger HM**, **Hulick PJ**, Sanders AR, Xu J. Validation of GenProb-T1D and its clinical utility for differentiating types of diabetes in a biobank from a US healthcare system. *J Diabetes*

Investig. 2025 Jan;16(1):10-15. doi: 10.1111/jdi.14297. Epub 2024 Aug 22. PMID: 39171755 Free PMC article.

Boehm D, Smith AR, Mansfield SA, Flynn KE, Fantus RJ, Glaser AP, **Helfand BT**, Helmuth M, Morgan TN, Lai HH, Sarma AV, Yang CC, Kirkali Z, Griffith JW. Factors associated with erectile dysfunction in men with lower urinary tract symptoms (LUTS): A Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study. *Transl Androl Urol.* 2025 Aug 30;14(8):2207-2217. doi: 10.21037/tau-2025-86. Epub 2025 Aug 15. PMID: 40949459

Broman MM, Lanman NA, Vickman RE, Cresswell GM, Kothandaraman H, Kolliegbo A, Paez Paez JS, Glaser AP, **Helfand BT**, Henry G, Strand DW, Franco OE, Crawford SE, Hayward SW, Ratliff TL. Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia. *bioRxiv* [Preprint]. 2024 Dec 30:2024.12.30.629739. doi: 10.1101/2024.12.30.629739. PMID: 39803459; PMCID: PMC11722345

Broman MM, Lanman NA, Vickman RE, Cresswell GM, Kothandaraman H, Kolliegbo A, Paez JSP, Glaser AP, **Helfand BT**, Henry G, Strand DW, Franco OE, Hayward SW, Ratliff TL. Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia. *Front Immunol.* 2025 Jul 7; 16:1585446. doi: 10.3389/fimmu.2025.1585446. eCollection 2025. PMID: 40692782

Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, **Helfand BT**, Linder BJ, Reynolds WS, Rovner ES, Souter L, Suskind AM, Takacs E, Welk B, Smith AL. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. *J Urol.* 2024 Jul;212(1):11-20. doi: 10.1097/JU.0000000000003985. Epub 2024 Apr 23. PMID: 38651651

Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, **Helfand BT**, Linder BJ, Reynolds WS, Rovner ES, Souter L, Suskind AM, Takacs E, Welk B, Smith AL. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. *NeuroUrol Urodyn.* 2024 Nov; 43(8): 1742-1752 doi: 10.1002/nau.25532. Epub 2024 PMID: 39010271

Cameron AP, Yang CC, Bradley CS, Griffith JW, Kirkali Z, Clemens JQ, Kreder KJ, Kenton KS, Andreev VP, Amundsen CL, Jelovsek JE, **Helfand BT**, Lai HH; LURN Study Group. Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN): An Introduction to the Urinary Urgency Phenotyping Protocol LURN II. *NeuroUrol Urodyn.* 2024 Jul 29. doi: 10.1002/nau.25566. Online ahead of print. PMID: 39075835

Campbell D, Ramsey S, Veenstra D, Pan M, Sen S, Litton G, **Brockstein B**, Young S, Fang A, Shah P. Diagnosis, Treatment, and Unmet Needs of Dedifferentiated Liposarcoma in the United States: A Multidisciplinary Delphi Study. *Cancers (Basel).* 2025 Aug 28;17(17):2815. doi: 10.3390/cancers17172815. PMID: 40940912

ChallaSivaKanaka S, Kakarla M, Vickman RE, Filipovich Y, Fitchev P, Alam MM, Talaty P, **Helfand BT**, Price D, Hayward SW, Crawford SE, Franco OE. DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer. *bioRxiv* [Preprint]. 2025 Sep 30:2025.09.28.679062. doi: 10.1101/2025.09.28.679062. PMID: 41256591 Free PMC article

Chan K, Palis BE, Cotler JH, Bleicher RJ, **Yao K**. Association of Surgeon Volume with Adherence to American Society of Breast Surgeons Surgical Quality Measures. *Ann Surg Oncol.* 2025 Oct;32(11):8144-8155. doi: 10.1245/s10434-025-17846-0. Epub 2025 Jul 25. PMID: 40711684 (accepted)

Chen N, Matossian M, **Saha P**, Rampurwala M, Kamaraju S, Hahn O, Howard F, Fleming G, Freeman J, Karrison T, Conzen S, Nanda R, Stringer-Reasor E. A Randomized Phase II Trial of Nab-Paclitaxel with or without Mifepristone for Advanced Triple-Negative Breast Cancer. *Breast Cancer Res Treat.* 2025 May; 211(1): 111-110. PMID: 39928262

Cloyd JM, Sarna A, Arango MJ, Bates SE, Bhutani MS, Bloomston M, Chung V, Dotan E, Ferrone CR, Gambino PF, Goenka AH, Goodman KA, Hall WA, He J, **Hogg ME**, Jayaraman S, Kambadakone A, Katz MHG, Khorana AA, Ko AH, Koay EJ, Kooby DA, Krishna SG, Larsson LK, Lee RT, Maitra A, Massarweh NN, Mikhail S, Muzaffar M, O'Reilly EM, Palta M, Petzel MQB, Philip PA, Reyngold M, Santa Mina D, Sohal DPS, Sundaresan TK, Tsai S, Turner KL, Vreeland TJ, Walston S, Washington MK, Williams TM, Wo JY, Snyder RA. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. *JAMA Surg.* 2024 Dec 4:e245191. doi: 10.1001/jamasurg.2024.5191. Online ahead of print. PMID: 39630427

Danilov K, **Bansal D**, Fowler N, et al. High tertiary lymphoid structure predicts immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer. *J Clin Oncol.* June 2025

Danilov K, **Bansal D**, Fowler N, et al. High tertiary lymphoid structure predicts immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer. *J Clin Oncol.* ASCO Annual Meeting. June 2025, Poster Presentation

David SP, **Dunnenberger HM**, Choi S, **DePersia A**, Ilbawi N, Ward C, Wake DT, **Khandekar JD**, Shannon Y, Hughes K, Miller N, Mangold KA, Sabatini LM, Helseth DL, Xu J, Sanders A, Kaul KL, **Hulick PJ**. Personalized medicine in a community health system: The NorthShore experience. *Front Genet.* 2023 Nov 28

David S, Saulsberry L, Pruitt J, **Dunnenberger H, Hulick P**, Ward C. Effects of Social Determinants and Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions. *Ann Fam Med*. 2024 Nov 1;21(Suppl 3):4606. doi: 10.1370/afm.22.s1.4606. PMID: 38271180. Free PMC article

de Graaf N, Augustinus S, Wellner UF, Johansen K, Andersson B, Beane JD, Björnsson B, Busch OR, Davis CH, Ghadimi M, Gleeson EM, Groot Koerkamp B, **Hogg ME**, van Santvoort HC, Tingstedt B, Uhl W, Werner J, Williamsson C, Zeh HJ, Zureikat AH, Abu Hilal M, Pitt HA, Besselink MG, Keck T; Global Audits on Pancreatic Surgery Group (GAPASURG). Transatlantic differences in the use and outcome of minimally invasive pancreatoduodenectomy: An international multi-registry analysis. *Surg Endosc*. 2024 Dec;38(12):7099-7111. doi: 10.1007/s00464-024-11161-7. Epub 2024 Sep 28. PMID: 39342074

Derman BA, Cooperrider J, Pula A, Simmons H, Kubicki T, Zonder J, Afrough A, **Grinblatt D**, Rosenblatt J, Anderson Jr LD, Kin A, Avigan D, Narula S, Rayani S, Jiang K, Major A, Karrison T, Jacob A, Jakubowiak AJ. Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant. *Hemasphere*. 19 Aug 2025. <https://doi.org/10.1002/hem3.70186>. PMID: 40838100

Dhungana A, Vannier A, Zhao F, Freeman JQ, **Saha P**, Sullivan M, **Yao K**, Flores EM, Olopade OI, Pearson AT, Huo D, Howard FM. Development and validation of a clinical breast cancer tool for accurate prediction of recurrence. *NPJ Breast Cancer*. 2024 Jun 15;10(1):46. doi: 10.1038/s41523-024-00651-5. PMID: 38879577; PMCID: PMC11180107

Diaz A, Hays S, **Hogg ME**. ASO Author Reflections: The Landmark Series: Minimally Invasive Pancreatic Resection — Past, Present, and Future. *Ann Surg Oncol*. 2025 Aug;32(8):5423-5425. doi: 10.1245/s10434-025-17595-0.

Epub 2025 Jun 2. PMID: 40456973 Free PMC article.

Diaz A, Hays S, **Hogg ME**. The Landmark Series: Minimally Invasive Pancreatic Resection for Ductal Adenocarcinoma, Updates, Trends, and Future Considerations. *Ann Surg Oncol*. 2025 Jun 7. doi: 10.1245/s10434-025-17483-7. Online ahead of print. PMID: 40483316 Review

Doll A, **Kopkash K**, Baker J. Emerging Role of Robotic Surgery in the Breast. *Clin. Breast Cancer*, 2024, ISSN 15268209, <https://doi.org/10.1016/j.clbc.2023.12.009>

Eisner R, Irani M, Grinblatt D (2025): A new pathogenic variant red cell membrane defect resulting in chronic hemolytic anemia. *Blood*, Volume 146 (Supplement 1), 6449-6449, 2025

Epstein R, **Dunnenberger HM, Hulick PJ**, Choi SH, **Newlin A, DePersia A**. The Breast Health Assessment: A family health history screening tool using the electronic health record to facilitate hereditary cancer genetic testing at the time of screening mammogram. 12th International Clinical Cancer Genomics Conference: Accelerating Progress in Precision Medicine for Cancer: The Time Is Now. Chicago, IL, 2024, Poster Presentation

Fantus RJ, Greenberg DR, Chang C, **Helfand BT**, Xu J, Wei J, Shoag JE, Nangia AK, Brannigan RE, Halpern JA. Novel reference range values for serum testosterone: A cross-sectional study of 200,000 males. *J Endocrinol Investig*. 2024 Sep;47(9):2261-2268. doi: 10.1007/s40618-024-02319-0. Epub 2024 Feb 22. PMID: 38383878

Fefferman M, Chan K, Cotler J, Thompson DM, Bleicher RJ, Kurtzman SH, Dietz JM, **Yao K**. Did the COVID-19 Consortium Recommendations Impact the Treatment of Breast Cancer during the COVID-19 Pandemic? *Breast Cancer Res Treat*. 2025; 211(1): 11-22

Fefferman M, Kuchta K, Nicholson K, Attai D, Victorson D, **Pesce C, Kopkash K, Poli E, Smith TJ, Yao K**. Patient Values

in Breast Cancer Surgical Decision-making — The WhySurg Study. *Am J Surg*. 2024 Jan;227:137-145

Fefferman M, Kuchta K, Wang CH, Nicholson K, Kopkash K, Pesce C, Poli E, Smith TW, **Yao K**. Rates of newly diagnosed breast cancer at commission on cancer facilities during the early phase of the COVID-19 pandemic. *Cancer Med*. 2024 Jan;13(1):e6874. doi: 10.1002/cam4.6874. PMID: 38140789

Fefferman M, Stump T, Thompson D, Simovic S, Medenwald R, **Yao K**. Patient-Reported Observations on Medical Procedure Timeliness (PROMPT) in Breast Cancer: A Qualitative Study. *Breast Cancer Res Treat*. 2024 Nov;208(1):123-132

Fefferman M, Thompson D, Wilke LG, Hwang S, Bleicher R, Freedman LM, Meisel JL, Kuchta K, **Yao K**. Commission on Cancer Center Performance with the New Breast Cancer Quality Measures: A Review of Historical Data. *Ann Surg Oncol*. 2024 (accepted)

Freeman JQ, Li JL, Fisher SG, **Yao K**, David SP, Huo D. Declination of Treatment, Racial and Ethnic Disparity, and Overall Survival in US Patients with Breast Cancer. *JAMA Network Open*. 2024 May;7(5):e249449

Freeman JQ, **Saha P**, Peiffer D, Chen N, Shubeck S, Yarlagadda S, Nanda R, Huo D, Howard FM. Adjuvant Chemotherapy for Hormone Receptor-Positive/HER2-Negative Breast Cancer in the Post-RxPONDER Era. Accepted. *JAMA Network*. October 2025, published December 2025

Freeman JQ, **Saha P**, Peiffer D, Chen N, Shubeck S, Yarlagadda S, Nanda R, Huo D, Howard FM. Adjuvant Chemotherapy for Hormone Receptor-Positive/HER2-Negative Breast Cancer in the Post-RxPONDER Era. Poster accepted to 18th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Sep 18-21, 2025. Baltimore, MD

George AK, Miocinovic R, Patel AR, Lomas DJ, Correa AF, Chen DYT, Rastinehad AR, Schwartz MJ, Sidana A, Stensland KD, **Helfand BT**, Gahan JC, Meng X, Yu A, Brisbane WG, Vourganti S, Barqawi AB, Uchio EM, Wysock JS, Polascik TJ, McClure TD, Fainberg J, Coleman JA. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-Risk Prostate Cancer: Results from the PRESERVE Trial. *Eur Urol*. 2025 Jul 19:S0302-2838(25)00346-X. doi: 10.1016/j.eururo.2025.06.003. Online ahead of print. PMID: 40685282

George AK, Miocinovic R, Patel AR, Lomas DJ, Correa AF, Chen DYT, Rastinehad AR, Schwartz MJ, Uchio EM, Sidana A, **Helfand BT**, Gahan JC, Yu A, Vourganti S, Barqawi AB, Brisbane WG, Wysock JS, Polascik TJ, McClure TD, Coleman JA. A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial. *Cancers (Basel)*. 2024 Jun 8;16(12):2178. doi: 10.3390/cancers16122178. PMID: 38927884

Glaser AP, Smith AR, Maglaque D, **Helfand BT**, Mohamed R, An H, Marquez M, Talaty P, Carolan P, Geller AM, Farina FR, Jensen SE, Griffith JW. Enhanced clinical decisions for management of benign prostatic hyperplasia using patient-reported outcomes: Protocol for a prospective observational study. *BMC Urol*. 2024 May 21;24(1):110. doi: 10.1186/s12894-024-01500-0. PMID: 38773430; PMCID: PMC11107033

Glaser AP, Xu J, **Helfand BT**. Do Genetics Predict Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia? *Urol Clin North Am*. 2025 Nov;52(4):475-487. doi: 10.1016/j.ucl.2025.07.001. Editorial Comment on "First-in-US Pilot Study of Aquablation in Ambulatory Surgery Centers: Clinical Outcomes and Economic Feasibility."

Glaser AP, XU J, **Helfand BT**. Do Genetics Predict Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia? *Urology*. 2025 Oct

15:S0090-4295(25)01005-2. doi: 10.1016/j.urology.2025.10.017. Online ahead of print. PMID: 41106517 No abstract available. Epub 2025 Aug 12. PMID: 41106977 Review

Hays SB, Al Abbas AI, Kuchta K, Rojas A, Ramirez Barriga M, Mehdi SA, **Haggerty S, Hedberg HM, Linn J, Talamonti M, Hogg ME**. Video Review Can Measure Surgical Robotic Skill Development in a Resident Robotic Hernia Curriculum: A Retrospective Cohort Study. *Ann Surg Open*. 2024 Oct 15;5(4):e500. doi: 10.1097/AS9.0000000000000500. eCollection 2024 Dec. PMID: 39729876

Hays SB, Kuchta K, Abreu AA, Chopra A, Farah E, Kannan A, Mehdi SA, Radi I, Ranson K, Rieser C, Rojas AE, Tcharni A, Boone BA, Paniccia A, Polanco PM, Schmidt CR, **Talamonti MS, Zeh HJ 3rd, Zureikat AH, Hogg ME**. ASO Visual Abstract: Multimodal Therapy May Be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Multicenter Analysis. *Ann Surg Oncol*. 2025 Mar 6. doi: 10.1245/s10434-025-17070-w. Online ahead of print. PMID: 40050484

Hays SB, Kuchta K, Abreu AA, Chopra A, Farah E, Kannan A, Mehdi SA, Radi I, Ranson K, Rieser C, Rojas AE, Tcharni A, Boone BA, Paniccia A, Polanco PM, Schmidt CR, **Talamonti MS, Zeh HJ 3rd, Zureikat AH, Hogg ME**. Multimodal Therapy May Be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Multicenter Analysis. *Ann Surg Oncol*. 2025 Jan 27. doi: 10.1245/s10434-025-16916-7. PMID: 39871074

Hays SB, Kuchta K, Espinosa C, Castillo-Flores S, Gebran A, Kannan A, Mehdi S, Nunez-Rocha R, Ranson K, Rojas A, Tcharni A, Boone B, Paniccia A, Polanco P, Schmidt C, **Talamonti M, Zeh H, Zureikat A, Hogg ME**. Dissecting the Risk of Bleeding and Pseudoaneurysm After Whipple and the Impact of Surgical Approach. *Accepted for AHPBA Presentation*.

Hays SB, Kuchta K, Mehdi SA, Rojas A, Omar K, **Talamonti M, Hogg ME**. Early Robotic Exposure Predicts Curriculum Performance and Stress for Residents. *Accepted for Oral Presentation at Academic Surgical Congress 2025*.

Hays SB, Kuchta K, Rojas AE, Mehdi SA, Schwarz JL, **Talamonti MS, Hogg ME**. Residency robotic biotissue curriculum: The next frontier in robotic surgical training. *HPB (Oxford)*. 2025 Jan 31:S1365-182X(25)00033-4. doi: 10.1016/j.hpb.2025.01.014. Online ahead of print. PMID: 39924371

Hays SB, Kuchta K, Rojas A, Mehdi SA, **Talamonti M, Hogg ME**. Balancing the Scales: Predictors of Performance and the Impact of a Resident Robotic Training Curriculum. *Submitted to American Surgical Association Annual Meeting 2025*.

Hays SB, Kuchta K, Rojas A, Mehdi S, **Talamonti MS, Hogg ME**. Robotic Inanimate Training Curriculum Improves Resident Robotic Performance Over Virtual Reality Curriculum Alone. *Oral Presentation at American College of Surgeons Clinical Congress 2024, presented in San Francisco, CA, October 21, 2024*.

Hays SB, Kuchta K, Suss N, Rojas A, Mehdi SA, Omar K, **Talamonti M, Hogg ME**. Minimally Invasive Surgery in Small Bowel GISTs Over 5cm: A Safe and Feasible Approach. *Accepted for Oral Presentation at Academic Surgical Congress 2025*.

Hays SB, Kuchta K, Mehdi S, Rojas A, **Talamonti M, Hogg M**. Resident Stress Correlates with Performance During Robotic Curriculum. *Submitted to Association for Surgical Education Annual Meeting 2025*.

Hays SB, Rojas AE, Kuchta K, Ramirez Barriga M, Mehdi SA, **Talamonti MS, Hogg ME**. How to integrate robotic training in surgical residency? An example of a 2-week robotic rotation. *J Robot Surg*. 2024 May 28;18(1):225. doi: 10.1007/s11701-024-01977-9. PMID: 38805107

Hays SB, Rojas A, Mehdi S, **Talamonti M, Hogg ME**. Robotic Repair of Common Hepatic Duct Injury (video abstract). *Accepted for Video Presentation at SAGES 2025*.

Heaphy CM, Patel S, Smith K, Wondisford AR, Lynskey ML, O'Sullivan RJ, Fuhrer K, Han X, Seethala RR, Liu TC, Cao D, Ertunc O, Zheng Q, Stojanova M, Zureikat AH, Paniccia A, Lee K, Ongchin MC, Pingpank JF, Zeh HJ, **Hogg ME**, Geller D, Marsh JW, Brand RE, Chennat JS, Das R, Fasanella KE, Gabbert C, Khalid A, McGrath K, Lennon AM, Sarkaria S, Singh H, Slivka A, Hsu D, Zhang JY, Nacev BA, Nikiforova MN, Wald AI, Vaddi N, De Marzo AM, Singhi AH, Bell PD, Singhi AD. Detection of Alternative Lengthening of Telomeres via Chromogenic In Situ Hybridization for the Prognostication of PanNETs and Other Neoplasms. *Mod Pathol*. 2024 Nov 9;38(3):100651. doi: 10.1016/j.modpat.2024.100651. Online ahead of print. PMID: 39522643

Helfand TY, Wei J, Mulford AJ, Tran H, Shi Z, Wang CH, Rifkin AS, Ashworth A, Zheng SL, **Helfand BT, Dunnenberger HM, Duggan D, Hulick PJ, DePersia A, Sanders AR, Xu J**. Polygenic Score Complements Family History and Lynch Syndrome Genes for Predicting Colorectal Cancer Risk. *JCO Precis Oncol*. 2025 Jul;9:e2500081. doi: 10.1200/PO-25-00081. Epub 2025 Jul 2. PMID: 40601893; PMCID: PMC12233176. Free PMC article

Helmuth ME, Smith AR, Glaser AP, Yang CC, Cameron AP, Henry Lai H, Griffith JW, Eric Jelovsek J, Quentin Clemens J, **Helfand BT**, Merion RM, Andreev VP; the LURN Study Group. Phenotyping Men with Lower Urinary Tract Symptoms: Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network. *Neurourol Urodyn*. 2025 Jan;44(1):178-193. doi: 10.1002/nau.25596. Epub 2024 Oct 7. PMID: 39370868; PMCID: PMC11665771

Hogg ME. Postoperative Outcomes with Minimally Invasive Liver Resection Based on ECOG Performance Status – Analysis of Multi-institutional Database. SAAS Sept 2024.

Hogg ME, Zeh HJ 3rd. Double Trouble — Do Smaller Incisions Create Bigger Problems? *JAMA Surg*. 2024 Dec 4. doi: 10.1001/jamasurg.2024.5563. Online ahead of print. PMID: 39630466

Hogg M, Zeh HJ 3rd. Learning curve stratified outcomes after robotic pancreatoduodenectomy: International multicentre experience. *Surgery*. 2024 Dec;176(6):1730-1731. doi: 10.1016/j.surg.2024.08.043. Epub 2024 Oct 10. PMID: 39389822

HoSang K, Bleicher RJ, **Yao KA**, Dietz JR, Williams AD. Low Socioeconomic Status at the Patient and Institution Level Impact Achievement of Breast Cancer Quality Standards. *Ann Surg Oncol*. 2025 Jun 2;32(12):8644-8655. doi: 10.1245/s10434-025-17529-w. PMID: 40456972 (accepted)

Huang S, Joshi A, Shi Z, Wei J, Tran H, Zheng SL, Duggan D, Ashworth A, Billings L, **Helfand BT**, Qamar A, Bulwa Z, Tafur A, Xu J. Combined polygenic scores for ischemic stroke risk factors aid risk assessment of ischemic stroke. *Int J Cardiol*. 2024 Jun 1;404:131990. doi: 10.1016/j.ijcard.2024.131990. Epub 2024 Mar 21. PMID: 38521508

Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, **Shevrin D**, et al. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line mCRPC with DNA Repair Defects (BRCAAway). *Clin Cancer Res*. 2024 Oct 1;30(19):4318-4328. doi: 10.1158/1078-0432.CCR-24-1402. PMID: 39115414

Isaacs WB, Wei J, Gielzak M, Wang Q, Snyder NA, Zheng S, Yan G, Lu L, Engelmann V, Rabizadeh D, Sysa-Shah P, Cornell B, Shi Z, Tran H, Lupold S, Lotan T, Dairo O, Walsh PC, **Helfand BT**, Lu J, Luo J, Cooney KA, Xu J. Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor-Sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer. *Eur Urol Focus*. 2025 Apr 3:S2405-4569(25)00044-6. doi: 10.1016/j.euf.2025.02.007. Epub ahead of print. PMID: 40189997

Karcioglu A. Oral Presentation at 50th World Congress of the International Society of Surgery (ISS/SIC) International Surgical Week (isw2024.org) Kuala Lumpur, Malaysia, August 25-29, 2024, Poster Presentation

Karcioglu AS, Trinh LN, McIlroy D, Okose OC, Wang B, Behr IJ, Cheung AY, Srikanthan A, Russell MD, Kamani D, Abdelhamid Ahmed AH, Randolph GW. Noninvasive monitoring of the vagus nerve during thyroid surgery using cutaneous adhesive and needle electrodes: What is the optimal configuration? *Head Neck*. 2024 Aug;46(8):1893-1901. doi: 10.1002/hed.27669. Epub 2024 Jan 31. PMID: 38294128

Kelly R, **Hulick P, Dunnenberger M**, Styn M, Profato-Partlow J, Kettner-Sieber D, Beidelschies M, Jackson S, Bakshi P, Christensen W, Gudar J, Numajiri A, Tran K, Parthasarathy V, Beer T. Falcon: Exact Sciences' multicancer early detection (MCED) real world evidence (RWE) registry. ASCO Annual Meeting. Chicago, IL, 2025, Poster Presentation

Khotkina N, **Bansal D**, Bagaev A, et al. Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy. *J Immunother*. November 2025

Khotkina N, **Bansal D**, Bagaev A, et al. Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy. SITC Annual Meeting. November 2025, Poster Presentation

Kong BL, Donnelly RS, Abubakar A, **Dunnenberger HM**, Jones JS, Rogers SL, Kisor D. STRIPE partners in precision medicine series: Pharmacist perspective. *Pharmacogenomics J*. 2024 Aug 14;24(5):26. doi: 10.1038/s41397-024-00347-w. PMID: 39138184 Review. No abstract available.

Kraftician JD, Kuchta K, Zenati MS, Hays SB, AIMasri S, Khachfe HH, Maalouf M, Desilva A, Hammad AY, Paniccia A, Lee KK, Zeh HJ, Zureikat AH, **Hogg ME**. Biotissue Curriculum Translates to Performance in the Operating Room for Gastrojejunostomy and Hepaticojejunostomy in Robotic Pancreaticoduodenectomy. *J Surg Educ*. 2024 Dec 26;82(2):103395. doi: 10.1016/j.jsurg.2024.103395. Online ahead of print. PMID: 39729876

Krantz SB. "I'll Be Back": This Is Just the Beginning of the AI Revolution. *Ann Surg Oncol*. 2024 Nov;31(12):7663-7664. doi: 10.1245/s10434-024-16046-6. Epub 2024 Aug 20. PMID: 39164602

Krantz SB, Mitzman B, Cooke DT, et al. Thoracic Surgery Outcomes Research Network (ThORN) Consensus Document on Defining a High-Quality Wedge Resection for Early-Stage Lung Cancer. *Ann Thorac Surg*. 2025 May;119(5):944-956. doi: 10.1016/j.athoracsur.2024.12.017. Epub 2025 Jan 8. PMID: 39793687

Krantz SB, Su KW. More for More's Sake Alone? Completion Lobectomy in the Setting of Occult Nodal Disease. *Ann Thorac Surg*. 2024 Sep;118(3):663-664. doi: 10.1016/j.athoracsur.2024.06.024. PMID: 39182951

Krantz SB. To Randomize or Not to Randomize: The Quest to Define "Good Judgment." *Ann Thorac Surg*. 2025 Jun 20:S0003-4975(25)00541-7. doi: 10.1016/j.j.2025.06.007. Online ahead of print. PMID: 40545024

Lam NG, Ahmadpour A, **Gimelfarb A**, **Nanda R**, **Ares WJ**. Epidural Spinal Cord Compression due to Extramedullary Hematopoiesis: Systematic Review of the Literature with an Illustrative Case. *World Neurosurg*. (2025) 193: 119-130. <https://doi.org/10.1016/j.wneu.2024.10.034>. PMID: 39427876

Lanman NA, Broman MM, Kothandaraman H, Cresswell GM, Awdalkreem GD, Wusiman D, Kolliegbo AK, Glaser AP, **Helfand BT**, Vickman RE, Yang J, Hayward SW, Ratliff TL. Immune dysregulation in

the prostates of C57BL/6^{Aire} mice mirrors that seen in human benign prostatic hyperplasia. *bioRxiv* [Preprint]. 2025 Aug 15:2025.08.12.669857. doi: 10.1101/2025.08.12.669857. PMID: 40832162

Lanman NA, Meco E, Fitchev P, Kolliegbo AK, Broman MM, Filipovich Y, Kothandaraman H, Cresswell GM, Talaty P, Antoniak M, Brumer S, Glaser AP, Higgins AM, **Helfand BT**, Franco OE, Wang CH, Crawford SE, Ratliff TL, Hayward SW, Vickman RE. Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia. *Front Immunol*. 2025 Jan 10;15:1494476. doi: 10.3389/fimmu.2024.1494476. PMID: 39867899; PMCID: PMC11757139

Lee K, Rosenberg CA, Patel A, **Saha P**. Identification of Most Common Concerns in Breast Cancer Survivors from 2019-2023 in the MRW Life Survivorship Program. Poster presented at San Antonio Breast Cancer Symposium (SABCS). December 2024. San Antonio, TX

Lorié B, Kuchta K, Rojas AE, Hays SB, Mehdi SA, Gurley M, Blumenthal R, **Talamonti MS**, **Hogg ME**. Outcomes After ERAS Pathway in Open and Robotic Pancreatic Surgery: A Retrospective Cohort Study. *J Surg Res*. 2025 Jul 22;313:465-478. doi: 10.1016/j.jss.2025.06.059. Online ahead of print. PMID: 40700961

Lowentritt BH, Jani AB, **Helfand BT**, Uchio EM, Morris MA, Michalski JM, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Impact of Clinical Factors on 18F-Flutolastat Detection Rates in Men with Recurrent Prostate Cancer: Exploratory Analysis of the Phase III SPOTLIGHT Study. *Adv Radiat Oncol*. 2024 May 1;9(8):101532. doi: 10.1016/j.adro.2024.101532. eCollection 2024 Aug. PMID: 39104875

Luskin MR, Yin J, Lozanski G, Curran E, Malnassy G, Mrózek K, Bloomfield CD, Cataland SR, Fulton N, Koltz J, Laplant B, Kour O, Powell BL, Vij R, Wang ES, **Grinblatt DL**, Stone RM, Uy

GL, Larson RA, Stock W. Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase I/II Study. *Cancer*. 2025 Feb 15;131(4), e35750. doi: 10.1002/cncr.35750. PMID: 39916320

Mahadevia H, Ponvilawan B, Al-Obaidi A, Buckley J, Subramanian J, **Bansal D**. Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: A case report. *Ther Adv Med Oncol*. March 2024

Matossian M, Shiang C, Dolcen D, Dreyer M, Hatogai K, Hall K, **Saha P**, Biernacka A, Sweis R, Karrison T, Chen N, Nanda R, Conzen SD. High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. *Breast Cancer Res Treat*. 2024 Nov 23. doi: 10.1007/s10549-024-07515-3. Epub ahead of print. PMID: 39579248

Matthews P, **Bansal D**, Pachynski R. A Phase 1b study of cabozantinib, nivolumab, with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings. ASCO Genitourinary Cancers Symposium. February 2025, Poster Presentation

Matthews P, **Bansal D**, Pachynski R. A Phase 1b study of cabozantinib, nivolumab, with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings. *J Clin Oncol*. February 2025.

Mavani PT, Goyal S, **Hogg ME**, Kamath AS, Iannitti DA, Simo KA, Helton WS, Serrano PE, Onkeni EO, Geller DA, Polanco PA, El-Hayek K, Warner SG, Cleary SP, Alseidi A, Zaidi MY, Russell MC, Maegawa F, Nguyen KT, Sarmiento JM, Maithel SK, Kooby DA, Shah MM. Postoperative Outcomes with Minimally Invasive Liver Resection Based on ECOG Performance Status – Analysis of Multi-institutional Database. *Surg Endosc*. 2025 Nov;39(11):7680-7689. doi: 10.1007/s00464-025-12184-4. Epub 2025 Sep 11. PMID: 40935944

McAdams CD, Clevenger N, Nicholson K, **Pesce C, Kopkash K, Poli E, Smith TW, Yao K**. Proportion of Patients with Ductal Carcinoma In Situ that Qualify for Observation Criteria Set Forth by Clinical Trials. *J Surg Oncol*. 2024 Sep 19. doi: 10.1002/jso.27858. PMID: 39295556. Epub ahead of print.

McAdams CD, Clevenger N, Nicholson K, **Pesce C, Kopkash K, Poli E, Smith TW, Yao K**. Proportion of Patients with Ductal Carcinoma In Situ that Qualify for Observation Criteria Set Forth by Clinical Trials. *J Surg Oncol*. 2025 Feb;131(2):115-123

McMillan A, **Alvi SA**, Al-Qurayshi Z, Fleishacker Z, Pagedar N, Buchakjian. Utility of Preoperative Positron Emission Tomography (PET) in Localizing Perforator Vessels of Anterolateral Thigh Free Flap. *Int J Otorhinolaryngol Head Neck Surg*. 2024 Jul 1. doi: 10.4236/ijohns.2024.134024

Monick SE, Hanson C, Hoehn KS, Hlubocky FJ, Stock W, Duvall A, McNeer J, Henderson T, Daugherty C, **Wang AY**. Feasibility of Symptom Burden Assessments and Early Palliative Care Integration in an Adolescent and Young Adult Leukemia Clinic. *J Adolesc Young Adult Oncol*. 2025 Oct 17. doi: 10.1177/21565333251389438. Epub ahead of print. PMID: 41122915

Morelli L, Zeh HJ 3rd, Zureikat AH, **Hogg ME**, Groot Koerkamp B, Besselink MG; Dutch Pancreatic Cancer Group. Video-Assessment of Surgical Performance in Robotic Gastro-Enterostomy During Pancreatoduodenectomy: Evaluating the Learning Curve and Risk of Delayed Gastric Emptying. *Ann Surg*. 2025 Mar 12

Murad L, Bouhadana D, Hamouda A, Arezki A, Layne E, Ganjavi C, Cacciamani GE, Glaser AP, **Helfand BT**, Zorn KC. Artificial Intelligence in Benign Prostatic Hyperplasia. *Urol Clin North Am*. 2025 Nov;52(4):509-522. doi: 10.1016/j.ucl.2025.07.005. Epub 2025 Aug 27. PMID: 41106980 Review

Murad L, Hamouda A, Bouhadana D, Lee N, Ohana I, Quintas JJ, Cabral J,

Leathead A, Saibi A, Corsi N, Chang C, Rodrigues T, Glaser AP, **Helfand BT**, Zorn KC. Safety and efficacy of aquablation in men 80 years or older: An analysis of the International Collaborative Aquablation Research Urology Society (ICARUS) real-world database. *World J Urol*. 2025 Oct 30;43(1):651. doi: 10.1007/s00345-025-05855-3. PMID: 41165821 No abstract available

Nelson OL, Rosales R, Turbov J, Thaete LG, Balamayooran G, Cline JM, Pike JW, **Rodriguez GC**. Vitamin D Significantly Inhibits Carcinogenesis in the Mogp-TAg Mouse Model of Fallopian Tube Ovarian Cancer. *Nutrients*. 2024 Sep 30;16(19):3318. doi: 10.3390/nu16193318. PMID: 39408285

Nhàn NTT, Filimon B, Fowler H, Ganesan S, Wang X, **Brockstein B**, Xu W. Abstract 654: Transcriptomic analysis of TGF- β -targeting oncolytic adenovirus and immune checkpoint inhibitor therapy in a triple-negative breast cancer mouse model. *Cancer Res*. (2025) 85 (8_Supplement_1): 654. doi.org/10.1158/1538-7445.AM2025-654 Poster Presentation: American Association for Cancer Research (AACR) Annual Meeting, April 2025

Nhàn NTT, Shin SC, Filimon B, Yang Y, Hu Z, **Brockstein B**, Xu W. Oncolytic adenovirus inhibits TNBC tumor growth/metastasis in mice by targeting TGF- β and overexpressing GM-CSF. *Mol Ther Oncol*. 2025 Jan 17;33(1):200936. doi: 10.1016/j.omton.2025.200936. eCollection 2025 Mar 20. PMID: 40104170

Nicholson K, Bleicher R, Stevens R, Dietz J, Wilke L, Kurtzman S, Sarantou T, **Yao K**. Impact of the National Accreditation Program for Breast Centers Reconstruction Standard on Reconstruction Rates at Commission on Cancer Centers with Breast Center Accreditation. *Ann Breast Surg*. 2024;8:14

Nielsen S, Kuchta K, Huang G, Zuber S, Holoubek S, **Karcioglu A**, Khokar A, Prinz R, Moo-Young T. Predicting disease-specific survival in patients

undergoing active surveillance for papillary thyroid carcinoma. *World J Surg*. 2025 Apr;49(4):1011-1021. doi: 10.1002/wjs.12434. Epub 2024 Dec 19. PMID: 39702859; PMCID: PMC11994147

Nielsen S, Kuchta K, Zuber S, Holoubek S, **Karcioglu A**, Khokar A, Prinz R, Moo-Young T. Predicting disease-specific survival in patients undergoing active surveillance for papillary thyroid carcinoma. *World J Surg*. 2025 pr;49(4):1011-1021. doi: 10.1002/wjs.12434. Epub 2024 Dec 19. PMID: 39702859

Nunez-Rocha RE, Castillo-Flores S, Al Abbas A, Kannan A, Hays S, Espinosa C, Mehdi S, Ranson K, Rojas A, Tcharni A, Boone B, Paniccia A, Schmidt C, **Talamonti M**, Zeh H, Zureikat A, **Hogg ME**, Polanco P. Predictors and Outcomes of Conversion from Robotic to Open Pancreatoduodenectomy: A Large Multicenter Analysis. *Submitted to Society of Surgical Oncology Annual Meeting 2025*.

Nusbaum DJ, Shi Z, Ashworth A, Tran H, Wei J, Dahmen AS, Agarwal PK, Labbate CV, **Helfand BT**, Xu J. A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors. *Urol Oncol*. 2025 Jun 5:S1078-1439(25)00180-2. doi: 10.1016/j.urolonc.2025.05.009. Epub ahead of print. PMID: 40480872

Oluyemi ET, Grimm LJ, Goldman L, Burlison J, Simanowith M, **Yao K**, Rosenberg RD. Rate and timeliness of diagnostic evaluation and biopsy following recall from screening mammography in the National Mammography Database. *J Am Coll Radiol*. 2024 Mar;21(3):427-438

Pavlovich CP, Wei J, Gielzak M, Shi Z, Tran H, Ashworth A, Lilly Zheng S, Walsh PC, Luo J, **Helfand BT**, Isaacs WB, Xu J. Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes. *Prostate*. 2025 Dec;85(16):1556-1561. doi: 10.1002/pros.70037. Epub 2025 Aug 18. PMID: 40825105

Ponvilawan B, Mahadevia H, Khan A, Subramanian J, **Bansal D**. Survival outcomes in single versus double immune checkpoint inhibitor in advanced non-small cell lung cancer: a meta-analysis. *J Thorac Oncol*. September 2024

Ponvilawan B, Subramanian S, **Bansal D**, et al. Clonal hematopoiesis and its association with lung cancer incidence and immunotherapy response: A meta-analysis. IASLC Annual Meeting. September 2025, Poster Presentation

Ponvilawan B, Subramanian S, **Bansal D**, et al. Clonal hematopoiesis and its association with lung cancer incidence and immunotherapy response: a meta-analysis. *J Thorac Oncol*. December 2025

Prassas B, Shi Z, Tran H, Wei J, Wang CH, Rifkin AS, Ashworth A, Zheng SL, Mulford AJ, Sanders AR, **Pesce C, Helfand BT, Dunnenberger HM, Duggan D, Hulick PJ, DePersia A, Xu J**. Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer-Specific Polygenic Scores. *Cancer Med*. 2025 Jun;14(11):e70990. doi: 10.1002/cam4.70990. PMID: 40462315; PMCID: PMC12133613

Proctor ES, Nusbaum DJ, Lee JM, Benirschke RC, Freedman A, Raster G, Glaser AP, Labbate CV, Higgins AM, **Helfand BT**, Glassy EF, Joseph L, Edelstein RA, Krupinski EA, Alnajjar H, Kearns JT, Groth JV. Bridging the gap: Evaluating ChatGPT-generated, personalized, patient-centered prostate biopsy reports. *Am J Clin Pathol*. 2025 May 17;163(5):766-774. doi: 10.1093/ajcp/aaqae185. PMID: 39838829

Rangelova E, Stoop TF, van Ramshorst TME, Ali M, van Bodegraven EA, Javed AA, Hashimoto D, Steyerberg E, Banerjee A, Jain A, Sauvanet A, Serrablo A, Giani A, **Hogg M**, et al. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: An international multicenter study. *Ann Oncol*. 2025 Jan 13;S0923-7534(25)00004-3. doi: 10.1016/j.annonc.2024.12.015. PMID: 39814200

Raster G, **Helfand BT**. Editorial Comment on "Robotic Waterjet Resection for Men with Prostate Cancer Suffering from Lower Urinary Tract Symptoms." *Urology*. 2025 Apr;198:158-159. doi: 10.1016/j.urology.2025.01.058. Epub 2025 Jan 30. PMID: 39892568

Rieser C, Corvino G, **Hays SB**, Lorie BD, McMichael WV, Mehdi SA, Rojas AE, Hogg ME. Minimally invasive training in surgical oncology: Current status and needs assessment. *Surg Onc Insight*. 2024 Jun 3

Rodriguez GC, Yozwiak M, Nelson OL, Zhang HH, Kim AA, Watkin W, Barton JK, Alberts DS. The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma. *Gynecol Oncol*. 2024 Jul;186:110-116. doi: 10.1016/j.ygyno.2024.04.007. Epub 2024 Apr 19. PMID: 38640774

Rojas A, Hays SB, Mehdi S, **Hogg ME**. When Things Go Wrong: Managing BDI During Whipple Procedure (video abstract). *Accepted for Video Mini-Oral Presentation at American Hepato-Pancreato-Biliary Association Annual Meeting 2025*.

Rojas A, Paterakos P, Hays S, **Hogg ME**. Management of Synchronous Metastatic Colorectal Cancer with Recurrent Liver Metastasis. *Am Surg*. 2025 Jul;91(7):1213-1214. doi: 10.1177/00031348251339527. Epub 2025 Apr 29. PMID: 40299765

Rojas A, Paterakos P, Hays SB, **Hogg ME**. Robotic approach for remnant cholelithiasis and CBD exploration for gallstones removal. *Cir Esp (Engl Ed)*. 2024 Dec;102(12):667-668. doi: 10.1016/j.cireng.2024.08.004. Epub 2024 Sep 27. PMID: 39343164

Romero IL, Lengyel E, Wahner Hendrickson AE, **Rodriguez GC**, Leath CA 3rd, Rocconi RP, Goodheart MJ, Dewdney S, Karrison T, Fleming GF, Yamada SD. Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. *Gynecol Oncol*. 2025 Mar;194:18-24. doi: 10.1016/j.ygyno.2025.02.001. PMID: 39923680

Russell M, Gild ML, Wirth LJ, Robinson B, **Karcioglu AS**, Iwata A, Athni TS, Abdelhamid Ahmed AH, Randolph GW. Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real-world experience. *Head Neck*. 2024 Oct;46(10):2496-2507. doi: 10.1002/hed.27735. Epub 2024 Mar 15. PMID: 38488238

Russell MD, Abdelhamid Ahmed AH, Feng Z, Shonka DC Jr, **Karcioglu AS**, Iwata AJ, Kyriazidis N, Siddiqui SH, Athni TS, Park JC, Wirth LJ, Zafereo ME, Randolph GW. Recovery of Recurrent Laryngeal Nerve Function with Neoadjuvant Treatment: Neural Characterization. *Laryngoscope*. 2024 Jul;134(7):3415-3419. doi: 10.1002/lary.31304. Epub 2024 Jan 24. PMID: 38264976

Saha P, Howard F, Stringer-Reasor E, Abdou Y, McMahan J, Zhang Y, Peterson J, Feiger B, Weitz M, Boughey J, Goetz M. Leveraging AI to Predict Recurrence-Free Survival in Breast Cancer Patients Through Image-Based Assessment of Tumor Characteristics. Poster presented during Poster Spotlight Session at San Antonio Breast Cancer Symposium (SABCS). December 2024. San Antonio, TX

Saha P, Israel O, Sanchez C, Eldridge L, Kuchta K, Yao KA. Impact of Obesity in Premenopausal Women with Early-Stage HR+/HER2- Breast Cancer Treated with Adjuvant Endocrine Therapy. Poster accepted as Oral Presentation and Poster Spotlight Session at San Antonio Breast Cancer Symposium (SABCS). December 2025. San Antonio, TX

Saha P, Kuchta K, Thompson D, **Yao KA**. Breast Cancer Trends and Outcomes Among Young Hispanic and Asian/Pacific Islander Women Age < 40 in the National Cancer Database (NCDB) adjusted for U.S. Population Data. Poster accepted for presentation at San Antonio Breast Cancer Symposium (SABCS). December 2025. San Antonio, TX

Saha P, Lee K, Kuchta K. Real-World Use of Ovarian Function Suppression in Women Younger Than 35 with Early-Stage ER+Her2- Breast Cancer. Poster presented at San Antonio Breast Cancer Symposium (SABCS). December 2024. San Antonio, TX

Saha P, Sanchez C, Israel O, Eldridge L, Kuchta K, **Yao KA**. Factors Associated with Real-World Use of Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women with Early-Stage HR+/Her2- Breast Cancer. Poster accepted for presentation at San Antonio Breast Cancer Symposium (SABCS). December 2025. San Antonio, TX

Sarim K, **Hulick P**, Webster G, et al. NFX-179 Topical Gel for the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 A Multicenter Phase 2b Study. Society of Investigative Dermatology Meeting. Dallas, TX, 2024, Poster Presentation

Schwarz JL, Kuchta K, Rojas A, Hays SB, Omar K, **Talamonti M, Hogg ME**. Robotic Operative Exposure Influences the Lasting Effects of a Resident Robotic Surgery Curriculum on Residents' Confidence and Perceived Skills. Accepted to 2025 American College of Surgeons Surgical Simulation Summit.

Shevrin D, Yang M, Sabatini L, Akroush M, Pfanzer N, et al. Clinical Outcomes from a Prospective Study of Comprehensive Genomic Testing in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Poster Presentation at 2025 ASCO Genitourinary Cancers Symposium

Shevrin D, Yang M, Sabatini L, Pfanzer N, Akroush, Alnajjar H, Helseth L. A Prospective Study of Comprehensive Genomic Testing to Identify Actionable Variants in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Poster presentation at 2024 ASCO Genitourinary Cancers Symposium

Shi Z, Mulford AJ, Tran H, Filipczak M, Gao S, Xie S, Lobel J, Wei J, Rifkin AS, Ashworth A, Zheng SL, Wiske C, Duggan D, **Helfand BT**, Qamar A, Sanders AR, Tafur AJ, Xu J. Development and validation of a genetic probability for venous thromboembolism. *Res Pract Thromb Haemost*. 2025 Apr 27;9(4):102876. doi: 10.1016/j.rpth.2025.102876. PMID: 40496845; PMCID: PMC12149594

Shi Z, Wei J, Rifkin AS, Wang CH, Billings LK, Woo JSH, **Talamonti MS, Jenkins Vogel MT, Moore E, Brockstein BE, Khandekar JD, Dunnenberger HM, Hulick PJ**, Duggan D, Zheng SL, Lee CJ, **Helfand BT**, Tafur AJ, Xu J. Cancer-Associated Thrombosis by Cancer Sites and Inherited Factors in a Prospective Population-Based Cohort. *Thromb Res*. 2023 Sep;229:69-72. doi: 10.1016/j.thromres.2023.06.023. Epub 2023 Jun 26. PMID: 37419004

Shin SC, Vickman RE, Filimon B, Yang Y, Hu Z, Mangold K, Prabhkar BS, Schreiber H, Xu W. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. *Cancer Gene Ther*. 2024 Apr;31(4):574-585. doi: 10.1038/s41417-024-00735-1. PMID: 38267626

Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, **Helfand BT**, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Implementation of Universal Germline Genetic Testing into Standard of Care for Patients with Prostate Cancer: The Time Is Now. *JCO Oncol Pract*. 2025 Jun;21(6):747-753. doi: 10.1200/OP-24-00626. Epub 2024 Dec 19. PMID: 39700441; PMCID: PMC12162241

Sisco M, Alva D, Kutcha K, Ghosh K, **Pesce C**, Seth A. Is Pre-Pectoral Implant Reconstruction Associated with Better

Physical Well-Being? American Society of Breast Surgeons Annual Meeting, 2025.

Smith DM, Douglas MP, Aquilante CL, Deverka PA, Devine B, **Dunnenberger HM**, Empey PE, Hertz DL, Monte AA, Moyer AM, Patel JN, Pratt VM, Saulsberry L, Scott SA, Voora D, Woodahl EL, Whirl-Carrillo M, Oni-Orisan A; Pharmacogenomics Global Research Network (PGRN) Publications Committee. Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. *Clin Pharmacol Ther*. 2025 Jun 4. doi: 10.1002/cpt.3736. Online ahead of print. PMID: 40468601 Review

Spear G, Lee K, DePersia A, Lienhoop T, **Saha P**. Updates in Breast Cancer Screening and Diagnosis. *Curr Treat Options Oncol*. 2024 Nov;25(11):1451-1460. doi: 10.1007/s11864-024-01271-8. Epub 2024 Oct 28. PMID: 39466539

Stringer-Reasor E, **Saha P**, Korcherginsky M, Lastra R, Baker G, Lenygel E, Karrison T, Olalde L, Mokrzycki E, Hahn O, Hoffman P, Conzen S, Fleming G, Nanda R. Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast and Recurrent/Persistent Epithelial Ovarian Cancer. *Breast Cancer Res Treat*. 2025 August. doi: 10.1007/s10549-025-07783-7. PMID: 40779028

Suss N, Kuchta K, Hays S, Shogan B, Talamonti T, **Hogg ME**. Choosing Minimally Invasive Surgery for Large Colorectal Tumors: Does Tumor Histology Matter? Accepted to *Academic Surgical Congress 2025*.

Tafur A, Sebai A, Shi Z, Wei J, Tran H, Zheng SL, **Krantz SB, Hensing T**, Mansfield AS, Xu J. Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study. *Lung Cancer*. 2025 Sep;207:108712. doi: 10.1016/j.lungcan.2025.108712. Epub 2025 Aug 25. PMID: 40882293

Temple LM. Healthcare profession student and medical cannabis: Knowledge, attitudes, beliefs and association with legal status, National Institute for Drug Abuse (NIDA) International Symposium, Montreal, Canada, June 15, 2024, Poster Presentation

Teshome M, Bleicher R, Boughey J, Margenthaler J, Mason H, **Pesce C**, Schultz K, Sharma R, Sweeting R, Plichta J. Analysis of the 2024 Breast Surgical Oncology Fellowship Match: Survey of Applicants' and Program Directors' Preferences Regarding In-Person Versus Virtual Interviews. *Ann Surg Oncol.* 2025 Oct;32(11):8514-8522. doi: 10.1245/s10434-025-18043-9. Epub 2025 Aug 23. PMID: 40849385. Submitted to SSO for publication.

Thodupunoori S, Auger S, Wallace A, **Karcioglu AS.** Association of Insurance Status and Socioeconomic Factors in Stage II Papillary Thyroid Carcinoma. Scientific Poster Presentation at AAO-HNS 2024 Annual Meeting and OTO Expo, Miami, FL, Sep 28-Oct 1, 2024

Thompson D, Fefferman M, Nicholson KM, Baron PL, Nguyen T, Schmitz K, Dietz JR, Bleicher RJ, Kuchta K, Simovic S, **Yao K.** Time from Screening to Treatment at Accredited Breast Centers in the United States. *JCO Oncol Pract.* 2024 Dec 2:OP2400516. doi: 10.1200/OP-24-00516. Epub ahead of print.

Thompson D, Fefferman M, Simovic S, Kuchta K, Bleicher R, Dietz J, Medenwald R, **Yao K.** Impact of Quality Improvement Interventions on Biopsy-to-Treatment Time in Breast Cancer: Results from the PROMPT Quality Collaborative of the National Accreditation Program for Breast Centers. *Ann Surg Oncol.* 2025 Oct;32(11):8256-8268. doi: 10.1245/s10434-025-17935-0. Epub 2025 Aug 9. PMID: 40783671 (accepted)

Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, **Shevrin DH**, Cooney M, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney

CJ. Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: Long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. *Ann Oncol.* 2025 Nov;36(11):1409-1413. doi: 10.1016/j.annonc.2025.08.004. Epub 2025 Aug 23. PMID: 40854410

van Ramshorst TME, van Hilst J, Boggi U, Dokmak S, Edwin B, Keck T, Khatkov I, Balduzzi A, Pulvirenti A, Ahmad J, Al Saati H, Alseidi A, Ausania F, Azagra JS, Balzano G, Björnsson B, Can FM, Cillo U, D'Hondt M, Efanov M, Erkan M, Espin Alvarez F, Esposito A, Ferrari G, Groot Koerkamp B, Gumbs AA, **Hogg ME**, Ielpo B, Ivanecz A, Jang JY, Kleive D, Kooby DA, Luyer MDP, Marchegiani G, Menon K, Molenaar IQ, Nagakawa Y, Nakamura M, Palumbo D, Piardi T, Ramia JM, Saint-Marc O, Salti GI, Strobel O, Vollmer CM, Wei AC, White S, Yoon YS, Zerbi A, Bassi C, Berrevoet F, Chan C, Coimbra FJ, Conlon KCP, Derveniz C, Falconi M, Frigerio I, Fusai GK, De Oliveira ML, Pinna AD, Primrose JN, Sauvanet A, Serrablo A, Smadi S, Alfieri S, Berti S, Butturini G, Casadei R, Coppola R, Di Benedetto F, Ettorre GM, Giuliante F, Jovine E, Memeo R, Pietrabissa A, Portolani N, Salvia R, Siriwardena AK, Asbun HJ, Besselink MG, Abu Hilal M. Standardizing definitions and terminology of left-sided pancreatic resections through an international Delphi consensus. *Br J Surg.* 2024 Apr 3;111(4):znae039. doi: 10.1093/bjs/znae039. PMID: 38686655 No abstract available.

Wang J, Lu P, Armstrong M, El-Hayek K, Cleary S, Asbun H, Alseidi A, Wei A, Tran Cao HS; SAGES HPB Committee (**Hogg M**). Advancing minimally invasive hepato-pancreato-biliary surgery: Ensuring safety with implementation. *Surg Endosc.* 2024 Aug;38(8):4365-4373. doi: 10.1007/s00464-024-10957-x. Epub 2024 Jun 17. PMID: 38886227

Xu J, Lu J, Gielzak M, Lilly Zheng S, Lu L, Wei J, Cornell B, Shi Z, Wang Q, Tran H, Engelmann V, Ashworth A, Lin K, Ross AE, Walsh PC, Marshall C, Luo J, Isaacs WB, **Helfand BT**, Pavlovich CP. Germline

Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines. *Prostate.* 2025 May 22. doi: 10.1002/pros.24918. Epub ahead of print. PMID: 40405569.

Xu W, Lin Q, Li Y, Filimon B, Shin SC, Olson M, Chen M. Abstract 6661: Profiling response to oncolytic adenovirus and immune checkpoint inhibitors by mass cytometry in a triple negative breast cancer mouse model. *Cancer Res* (2024) 84 (6_Supplement): 6661. <https://doi.org/10.1158/1538-7445.AM2024-6661>. Poster Presentation: American Association for Cancer Research (AACR) Annual Meeting, March 2024

Zorn KC, Chakraborty A, Chughtai B, Mehan R, Elterman D, Nguyen DD, Bouhadana D, Glaser AP, Marhamati S, Barber N, **Helfand BT.** Safety and Efficacy of Same-Day Discharge for Men Undergoing Contemporary Robotic-Assisted Aquablation Prostate Surgery in an Ambulatory Surgery Center Setting — First Global Experience. *Urology.* 2025 Jan;195:132-138. doi: 10.1016/j.urology.2024.08.006. Epub 2024 Aug 17. PMID: 39159759

Zorn KC, Chakraborty A, Chughtai B, Mehan R, Elterman D, Nguyen DD, Bouhadana D, Glaser AP, Marhamati S, Barber N, **Helfand BT.** Reply to Editorial Comment on "Safety and Efficacy of Same-Day Discharge for Men Undergoing Contemporary Robotic-Assisted Aquablation Prostate Surgery in an Ambulatory Surgery Center Setting — First Global Experience." *Urology.* 2025 Jan;195:140-141. doi: 10.1016/j.urology.2024.10.035. Epub 2024 Oct 19. PMID: 39433091

Zwart MJW, van den Broek BLJ, Pajens DSJ, Zwetsloot SLM, Comandatore A, Busch OR, Tran TCK, Luyer MD, Schreinemakers J, Wijsman JH, van der Schelling GP, de Hingh IHJT, Mieog JSD, Bonsing BA, Takagi K, de Wilde RF, Zwart MJW, van den Broek BLJ, Zwetsloot SLM, Busch OR, Tran TCK, Luyer MD, Schreinemakers J, Wijsman

JH, van der Schelling GP, de Hingh IHJT, Mieog JSD, Bonsing BA, Takagi K, de Wilde RF, Zeh HJ 3rd, Zureikat AH, **Hogg ME**, Groot Koerkamp B, Besselink MG; Dutch Pancreatic Cancer Group. Video Grading of Bile Duct Anastomoses During Robotic Pancreatoduodenectomy Predicts Bile Leak and Identifies the Learning Curve: A Multicenter Study. *Ann Surg*. 2025 Feb 17

Zeidan AM, Yu R, Wang Y, Lan Z, **Grinblatt DL**, Elsouda D, Spalding J, Block A, Touya M, Walker MS, Pandya BJ. Streamline: Retrospective Cohort Study of FMS-like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia: Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis. *Acta Haematol*. 2025 Apr 14:1-20. doi: 10.1159/000545384. PMID: 40228486

Peer Review

Botta G, Abdelrahim M, Drengler R, Aushev V, Esmail A, Lalotus G, Brewer C, George G, Abbate S, Chandana S, Tejani M, Malla M, **Bansal D**, et al. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. *Oncologist*. July 2024

Khan AW, Chandra S, Mahadevia H, Subramanian J, Ponvilawan B, **Bansal D**. Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis: A Case Series. Exploration of Targeted Anti-Tumor Therapy. November 2025

Ponvilawan B, **Bansal D**, Nagla A, Ramakrishna R, Subramanian J. Long-Term Survival Outcomes by Number of ICI in PD-L1 Negative Metastatic NSCLC: A Meta-Analysis. *JAMA Network Open*. February 2025

Ponvilawan B, Khan A, Subramanian J, **Bansal D**. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors. *Cancers*. March 2024

Ponvilawan B, Mahadevia H, Qasim H, Sharma P, **Bansal D**, Subramanian J. Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Clin Lung Cancer*. February 2024


Ponvilawan B, Subramanian J, **Bansal D**. The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC. *J Thorac Oncol*. August 2024

Sharma P, Mahadevia H, Donepudi S, Kujtan L, Gustafson B, Ponvilawan B, Al-obaidi A, Subramanian J, **Bansal D**. A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review. *Clin Lung Cancer*. April 2024

Zolotov Y, Edelstein OE, **Temple LM**, Kogan M, Romem-Porat SL, Reznik A, Isralowitz R. Education, training, and perceptions of physician competency among medical cannabis patients in Israel. *Complement Ther Med*. 2025 Jun;90:103172. Epub 2025 Apr 2. PubMed PMID: 40185288

Zolotov Y, Edelstein OE, **Temple LM**, Kogan M, Romem-Porat SL, Reznik A, Isralowitz R. Response to Letter Regarding "Education, training, and perceptions of physician competency among medical cannabis patients in Israel." *Complement Ther Med*. 2025 Jul 16. Epub ahead of print. PubMed PMID: 40681023

2025 Physician Directory




Matthew Adess, MD

Medical Director, Highland Park Kellogg Cancer Center
Expertise: GI Oncology; Benign and Malignant
Locations: GBK, HPK




Marc Alonzo, MD

Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Sameer Alvi, MD

Section Head, Head & Neck Oncologic Surgery
 Department of Surgery, Division of Otolaryngology
Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Salivary Gland Surgery; Microvascular Reconstruction; Transoral Robotic Surgery
Locations: EVK, NMB, SW



Saad Arain, MD

Expertise: Benign and Malignant Hematology
Locations: GBK, HPK




Tariq Azam, MD

Director of Cardio-Oncology
Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity
Locations: BN, GB



Ami Badami, MD

Expertise: Genitourinary Cancer
Locations: EVK, SWK



Julian Bailes, MD

Chair, Department of Neurosurgery; Co-Director, NorthShore Neurological Institute
Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery
Locations: EV, HPH, NCH




Dhruv Bansal, MD

Program Director for Immunotherapy
Expertise: Immunotherapy; Lung Cancer; Melanoma
Locations: EVK, HPK



Raj Bhanvadia, MD

Expertise: Bladder and Kidney Cancer
Locations: EV, GB, SW



William Bloomer, MD

Chair, Department of Radiation Oncology
Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer
Locations: EH, HPH




Francois Blumenfeld-Kouchner, DO

Expertise: Hospice and Palliative Medicine
Locations: EV, GB, HP, NCH, SK



Bruce Brockstein, MD

Director, Endeavor Health Cancer Institute Kellogg Cancer Center; Division Head, Hematology/Oncology; Endeavor Health Kellogg-Scanlon Chair of Oncology; Physician Executive, Endeavor Health Medical Group-Oncology
Expertise: Head and Neck Cancers; Melanoma; Sarcoma
Locations: EVK, HPK



Temu Brown, MD

Expertise: Internal Medicine; Hospice and Palliative Medicine
Locations: EV, GB, HP, NCH, SK



Elizabeth Burke, MD

Expertise: Breast and Facial Reconstruction, Including Facial and Breast Reconstruction; Microsurgery; Skin Cancer; Aesthetic Breast and Body Surgery
Location: NMB



Nicholas Campbell, MD

Expertise: Lung Cancer; Head and Neck Cancers
Locations: EVK, HPK, SW




Carolina Soto Chervin, MD

Expertise: Immunotherapy; Lung Cancer; GI Cancer
Locations: EVK, HPK



Shakeel Chowdhry, MD

Expertise: Surgery for Aneurysms; Endovascular Treatment for Aneurysms; Arteriovenous Malformations (AVMs); Interventional Stroke Therapy; Brain Tumors; Pituitary Tumors; Spinal Tumors
Locations: EV, GB, LCN, NCH



John Cieslak, MD

Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Jeffrey Cilley, MD

Medical Director, Swedish Hospital Cancer Center
Expertise: Benign and Malignant Hematology; Breast Cancer; Medical Oncology
Location: SW



Allison DePersia, MD
Expertise: Medical Genetics, Hematology Oncology; High-Risk Breast Cancer
Location: EV



Nisha Desai, MD
Expertise: Adult and Pediatric Dermatology; General Dermatology; Laser and Surgical Treatment of Birthmarks; Hemangioma
Locations: LV, SK



Michael Dombrowski, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Marie Dreyer, MD
Expertise: Head and Neck Cancers; Lung Cancer
Locations: EVK, GBK



Robert Eisner, DO
Expertise: Benign and Malignant Hematology; Cellular Therapy
Locations: EV, GBK



Shannon Ewing, MD
Expertise: Skin Cancer
Location: SK



Brendan Gilmore, MD
Expertise: GI Oncology; Benign and Malignant Hematology
Location: SW



Alla Gimelfarb, MD
 Associate Division Head of Hematology/Oncology
Expertise: Benign and Malignant Hematology
Location: GBK



David Grinblatt, MD
 Medical Lead, Cellular Therapy
Expertise: Benign and Malignant Hematology; Cellular Therapy
Location: EVK



Sebouh Gueykian, MD
 Section Head, Interventional Radiology
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Harold Hamann, MD
Expertise: General Urology; Endourology; Kidney Stones; Benign Prostate Hyperplasia; Prostate Cancer; Kidney Cancer
Location: SH



Britt Hanson, DO
Expertise: Benign and Malignant Hematology; Melanoma
Location: HPK



Herbert Mason Hedberg, MD
Expertise: Gastrointestinal, Esophageal and General Surgery
Locations: EV, HP



Brian Helfand, MD, PhD
 Division Head, Urology
Expertise: Prostate Cancer; Benign Prostatic Hyperplasia; Laparoscopic Surgery; Robotic Assisted Surgery; Laser Surgery
Location: GB



Anshu Hemrajani, MD
Expertise: Breast Cancer
Locations: GBK, HPK, SW



Thomas Hensing, MD, MSc
 System Physician Vice President, Ambulatory Quality
Expertise: Lung Cancer
Locations: EVK, GBK




Melissa Hogg, MD, MS
 Division Head, Gastrointestinal and General Surgery; Director, Liver and Pancreas Surgery
Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Primary and Metabolic Liver Tumors; Neuroendocrine Tumors; Cancers of the Stomach and Duodenum; Benign Hepatobiliary
Locations: EVK, SW



Peter Hulick, MD, MMSc
 Division Head, Medical Genetics; Medical Director, Mark R. Neaman Center for Personalized Medicine
Expertise: Cardiovascular and Cancer Genetics; Pharmacogenomics; Personalized Medicine
Location: EV




Javed Imam, MD
Expertise: Benign and Malignant Hematology; Medical Oncology
Location: SW




Monica Janeczek, MD
Expertise: Skin Cancers
Location: LB




Mary Tilley Jenkins Vogel, MD
Expertise: Gynecologic Oncology
Locations: EVK, GBK, SW




Andrew Johnson, MD
Expertise: Brain and Spine Tumors
Locations: LV, SW




Lynne Kaminer, MD
 Section Head, Hematology
Expertise: Benign and Malignant Hematology; Cellular Therapy
Location: EVK



Amanda Silver Karcioğlu, MD
 Section Head, Endocrine Surgery; Department of Surgery, Division of Otolaryngology
Locations: EVK, LB, SKM




Deborah Katz, MD
Expertise: Benign and Malignant Hematology
Locations: GBK, HPK

**James Kearns, MD**


Expertise: Prostate Cancer; Benign Prostatic Hyperplasia; Laparoscopic Surgery; Robotic Assisted Surgery; Laser Surgery
Locations: EV, GB

**Tae Kim, MD**

Expertise: Minimally Invasive Colon; Colon and Rectal Cancer; Inflammatory Bowel Disease
Locations: HPS, GB

**Katherine Kopkash, MD**

Director of Oncoplastic Breast Surgery
Expertise: Breast Cancer; Oncoplastic Breast Surgery; Breast Health; Breast Disease and Surgery
Locations: EV, GB

**Seth Krantz, MD**

Chairman, NorthShore Cancer Committee; Division Head, Thoracic Surgery, Endeavor Health Department of Surgery
Expertise: Lung Cancer, Esophageal Cancer, Benign Esophageal Disease, Mediastinal Masses, Diseases of the Chest Wall and Pleura, Minimally Invasive Surgery, Thymoma, Robotic Surgery, Bronchoscopy, Endobronchial Ultrasound, Esophagoscopy, Slipping Rib Syndrome
Locations: EVK, HPK, NCH

**Monika Krezalek, MD**


Director, Rectal Cancer Program, Endeavor Health Cancer Liaison Physician, NorthShore Cancer Committee
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; Advanced Lower Endoscopy
Locations: EV, HPH

**Daniel Laich, DO**

Expertise: Spine Tumors
Location: SW

**Eden Lake, MD**

Expertise: Melanoma; Skin Cancer
Locations: LB, SK

**Elyse Lambiase, MD**

Expertise: Breast Cancer, Benign and Malignant Hematology; Medical Oncology
Location: SW

**Teresa Law, MD**

Expertise: Breast Cancer
Locations: EVK, HPK

**Mia Levy, MD, PhD**

Director for Innovation, Hematology/Oncology
Expertise: Breast Cancer
Locations: EVK, HPK

**Ross Levy, MD**


Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery; Cosmetic Surgery
Location: SK

**Melissa Hachen Lippitt, MD, MPH**

Expertise: Gynecologic Oncology
Locations: EVK, GBK

**Natalie Liu, MD**

Expertise: Minimally Invasive Surgery; Esophageal Surgery; Gastric Surgery; Bariatric Surgery; Flexible Endoscopy; Gallbladder Surgery; Complex Hernia Surgery
Locations: EV, GB, HPS

**James McGrath, DO**

Expertise: Palliative Medicine
Locations: EV, GB, HP, NCH, SK

**Gregg Menaker, MD**

Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery; Cosmetic Surgery
Location: SK

**Douglas Merkel, MD**

Expertise: Breast Cancer
Locations: EVK, GBK, HPK

**Cecylia K. Mizera, MD**

Expertise: Breast Surgery
Location: SW

**Tricia Moo-Young, MD**

Expertise: Minimally Invasive Approaches to Endocrine Disorders; Thyroid and Parathyroid Surgery; Adrenal Disorders; Cancer and Disease Management
Locations: HPH, SK

**Elena Moore, MD**


Expertise: Gynecologic Oncology
Locations: EVK, HPK

**Joseph Muldoon, MD**

Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease
Locations: EV, GB

**Ranjeev Nanda, MD**

Expertise: Stereotactic Radiosurgery; Brain Tumors; Head and Neck Cancers; Prostate Cancer
Locations: EH, GBH

**Andrea Newtson, MD**

Expertise: Gynecologic Oncology
Locations: EVK, HPK

**Kristian Novakovic, MD**

Expertise: Bladder Cancer; Kidney Cancer; Prostate Cancer; Minimally Invasive Techniques: Laparoscopy and da Vinci Robotic
Locations: EV, GB

**Sangtae Park, MD, MPH**

Expertise: Prostate Cancer; Urologic Oncology
Locations: EV, GB

**Thomas Pathiyil, MD**

Expertise: Internal Medicine; Hospice and Palliative Medicine
Location: NCH



Anita Vasan Pattani, DO
Expertise: Internal Medicine; Hospice and Palliative Medicine
Locations: EV, GB, HP, SK



Gustavo Rodriguez, MD
 Division Head, Gynecologic Oncology
Expertise: Gynecologic Oncology
Location: EVK



Sahana Somasegar, MD
Expertise: Gynecologic Oncology
Locations: EVK, GBK, HPK



Catherine Pesce, MD
 Division Head, Surgical Oncology
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Locations: EVB, HPB




Carol Rosenberg, MD
 Director, Preventive Health Initiatives; Director, Myra Rubenstein Weis Living in the Future (LIFE) Cancer Survivorship Program
Expertise: Cancer Survivorship
Location: HPH



James Spitz, MD
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancers; Advanced Lower Endoscopy
Locations: GB, HPS, VH



Nicklas Pfanzerter, MD
Expertise: Genitourinary Cancer; Melanoma
Locations: GBK, HPK




Poornima Saha, MD
Expertise: Breast Cancer
Locations: EVK, GBK



Katherine Wailen Su, MD
Expertise: Lung Cancer, Esophageal Cancer, Benign Esophageal Disease, Mediastinal Masses, Diseases of Chest Wall and Pleura, Minimally Invasive Surgery, Thymoma, Robotic Surgery, Paraesophageal Hernias, Advanced Endoscopy/Bronchoscopy, Pectus Excavatum Repair
Locations: EV, GB



Elizabeth Poli, MD
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Locations: GBB, HPB, VH



Akhil Seth, MD
Expertise: Breast Reconstruction; Aesthetic Breast and Body Surgery; Oncologic Reconstruction
Location: NMB



Auddie Sweis, MD
Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery
Locations: LB, SW



Ariel Polish, MD
Expertise: GI Cancer; Benign and Malignant Hematology; Lung Cancer
Locations: EVK, GBK




Arif Shaikh, MD
Expertise: Stereotactic Radiosurgery; Head and Neck Cancers; Lung Cancer; Gynecologic and Breast Tumors
Locations: EH, GBH, HPH



Leslie Mendoza Temple, MD
 Medical Director, Integrative Medicine
Expertise: Integrative Medicine
Location: GP



Amit Pursnani, MD
Expertise: Cardio-Oncology
Location: SK



Daniel Shevrin, MD
 Medical Director, Glenbrook Kellogg Cancer Center
Expertise: Prostate Cancer; Genitourinary Cancer
Locations: EVK, GBK



Christopher Trevino, MD
 Division Head, Neuro-Oncology
Expertise: Neuro-Oncology, Brain and Spinal Cord Tumors
Locations: EV, GBK



Vathsala Raghavan, MD
Expertise: Thyroid Cancer; Breast Cancer; Gynecologic Oncology; Head and Neck Cancers
Locations: EH, GBH, HPH



Hayley Silver, MD
Expertise: Benign Prostate Hyperplasia; Kidney Stones; Male Bladder Symptoms; Vasectomy
Locations: EV, HP, SW



Michael Ujiki, MD
 Endeavor Health Physician Executive; Surgery Chair, Department of Surgery
Expertise: Minimally Invasive Surgery; Esophageal Surgery; Gastric Surgery; Bariatric Surgery; Flexible Endoscopy; Gallbladder Surgery
Locations: EV, GB



Joseph Raviv, MD
 Division Head, Otolaryngology
Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery
Locations: NMB, SK



Mark Sisco, MD
 Division Head, Plastic Surgery
Expertise: Aesthetic Surgery; Breast and Body Surgery; Breast Reconstruction; Microsurgery
Location: NMB



Elaine Lee Wade, MD
Expertise: Breast Cancer
Location: GBK



Sidney Regalado, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Thomas (T.J.) Smith, MD
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Locations: SK, SW

**Jason Waldinger, MD**

Division Head, Dermatology
Expertise: General Dermatology;
 Skin Cancer
Location: LB

**Amy Wang, MD**

Expertise: Benign and
 Malignant Hematology;
 Cellular Therapy
Location: EVK

**K.T. Weber, MD**

Expertise: Minimally Invasive
 Colon and Rectal Surgery
Locations: GB, SK, SWS

**Lauren Wiebe, MD**

Interim Director of
 Gastrointestinal Medical
 Oncology
Expertise: GI Oncology,
 Palliative Care
Locations: EVK, GBK

**Ricky Wong, MD**

Expertise: Pituitary Tumors;
 Brain and Skull Base Tumors;
 Trigeminal Neuralgia
Locations: BG, EV, GB, SW

**Katharine Yao, MD**

Vice Chair, Research and
 Development, Department of
 Surgery
Expertise: Breast Cancer;
 Breast Health; Breast Disease
 and Surgery
Location: GBB

**Andrew Zelby, MD**

Expertise: Brain, Pituitary
 Tumors
Locations: LV, SW

Endeavor Health Cancer Conferences

Breast Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, Mondays, 7:30 am
 Glenbrook and Highland Park Hospitals Videocast

Endeavor Health Swedish Hospital
 Anderson Pavilion Leadership Room, Wednesdays, 12:00 pm

Colorectal Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, 2nd and 4th Fridays, 7 am
 Glenbrook and Highland Park Hospitals Videocast

Endeavor Health Swedish Hospital
 Every other Thursday, 7:30 am

General Cancer Conferences

Endeavor Health Swedish Hospital
 3rd Mondays, 12:00 pm
 Swedish Hospital Videocast

Genitourinary Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, 1st and 3rd Fridays, 7 am
 Glenbrook Hospitals Videocast

Gynecology Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, Thursdays, 7 am
 Glenbrook and Highland Park Hospitals Videocast

Head and Neck Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, 1st and 3rd Thursdays, 8 am

Hematology/Pathology Conferences

Endeavor Health Evanston Hospital
 Heme/Path Room 1914A, Tuesdays, 8 am
 Glenbrook and Highland Park Hospitals Videocast

Hepatic Biliary Pancreatic Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, Tuesdays, 7 am
 Glenbrook and Highland Park Hospitals Videocast

Neuro-Oncology Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, 2nd and 4th Wednesdays, 7:30 am
 Glenbrook and Highland Park Hospitals Videocast

Sarcoma/Melanoma Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, 1st and 3rd Wednesdays, 8 am
 Glenbrook and Highland Park Hospitals Videocast

Thoracic Cancer Conferences

Endeavor Health Evanston Hospital
 Kellogg Room G868-870, Tuesdays, 12 pm
 Glenbrook and Highland Park Hospitals Videocast

Locations

Arlington Heights Endeavor Health Medical Group

880 W. Central Road, Suite 7200,
Arlington Heights, IL 60005

Arlington Heights Infusion Center

3060 Salt Creek Lane, Suite 1100,
Arlington Heights, IL 60005

Bannockburn Cardiovascular Institute (BN)

2151 Waukegan Road, Suite 100,
Bannockburn, IL 60015

Chicago Endeavor Health Brain & Spine Institute (SW)

5115 N. Francisco Avenue,
Chicago, IL 60625

Elmhurst Hospital Radiation Oncology

177 E. Brush Hill Road,
Elmhurst, IL 60126

Elmhurst Swedish Hospital Nancy W. Knowles Hematology/Oncology Clinic and Infusion Center

177 E. Brush Hill Road, Suite 1000,
Elmhurst, IL 60126

Endeavor Health Medical Group/Neurosciences Institute

5115 N. Francisco Avenue,
Chicago, IL 60625

Endeavor Health Medical Group

1200 S. York Street, Suite 4240,
Elmhurst, IL 60126

Endeavor Health Medical Group

2180 Pfingsten Road, Suite 2000,
Glenview, IL 60026

Evanston Breast Center (EVB)

2650 Ridge Avenue,
Evanston, IL 60201

Evanston Hospital (EH)

2650 Ridge Avenue,
Evanston, IL 60201

Evanston Hospital Radiation Oncology (EH)

2650 Ridge Avenue,
Evanston, IL 60201

Evanston Specialty Suites (EV)

1000 Central Street,
Evanston, IL 60201

Evanston Swedish Hospital Kellogg Cancer Center (EVK)

2650 Ridge Avenue,
Evanston, IL 60201

Glenbrook Breast Center (GBB)

2050 Pfingsten Road, Suite 130,
Glenview, IL 60026

Glenbrook Hospital (GBH)

2100 Pfingsten Road,
Glenview, IL 60026

Glenbrook Hospital Radiation Oncology (GBH)

2100 Pfingsten Road,
Glenview, IL 60026

Glenbrook John and Carol Walter Ambulatory Care Center (GB)

2180 Pfingsten Road,
Glenview, IL 60026

Glenbrook Medical Building (GBM)

2050 Pfingsten Road, Suite 128,
Glenview, IL 60026

Glenbrook Swedish Hospital Kellogg Cancer Center (GBK)

2180 Pfingsten Road, Suite 1000,
Glenview, IL 60026

Glenview Park Center (GP)

2400 Chestnut Avenue,
Glenview, IL 60026

Gurnee Ambulatory Care Center (GR)

7900 Rollins Road,
Gurnee, IL 60031

Highland Park Ambulatory Care Center (HPS)

757 Park Avenue West,
Highland Park, IL 60035

Highland Park Breast Center (HPB)

777 Park Avenue West, Suite B400,
Highland Park, IL 60035

Highland Park Hospital (HPH)

777 Park Avenue West, Room 1260,
Highland Park, IL 60035

Highland Park Hospital Radiation Oncology (HPH)

757 Park Avenue West,
Highland Park, IL 60035

Highland Park Medical Building (HP)

767 Park Avenue West, Suite B100,
Highland Park, IL 60035

Highland Park Swedish Hospital Kellogg Cancer Center (HPK)

Ellen Marks Ambulatory Care Center
757 Park Avenue West, Suite 1810,
Highland Park, IL 60035

Lake Bluff Medical Building (LB)

71 Waukegan Road, Suite 700,
Lake Bluff, IL 60044

Lakeview Medical Group (LV)

3122 N. Ashland Avenue,
Chicago, IL 60657

Lincolnshire Endeavor Health Medical Group (LCN)

920 Milwaukee Avenue, Suite 210,
Lincolnshire, IL 60069

Mount Prospect Medical Building (MP)

1329 Wolf Road,
Mount Prospect, IL 60056

Naperville Edward's Hospital Radiation Oncology

120 Spalding Drive, Suite 111,
Naperville, IL 60540

Naperville Swedish Hospital Hematology/Oncology Clinic and Infusion Center

120 Spalding Drive, Suite 211,
Naperville, IL 60540

Northbrook Medical Building (NMB)

501 Skokie Boulevard,
Northbrook, IL 60062

NorthShore Medical Group — Skokie (SKM)

9933 Woods Drive, Suite 200,
Skokie, IL 60077

Northwest Community Healthcare (NCH)

880 West Central Road, Suite 4100,
Arlington Heights, IL 60005

**Plainfield Swedish Hospital
Hematology/Oncology Clinic and
Infusion Center**

24600 W. 127th Street, Suite 2000,
Plainfield, IL 60585

Skokie Ambulatory Care Center (SK)

9650 Gross Point Road, Suite 3000,
Skokie, IL 60076

Skokie Medical Group (SKM)

9669 Kenton Avenue, Suite 206,
Skokie, IL 60076

Swedish Hospital (SW)

Breast Center

5140 N. California Avenue, Suite 420-GMP,
Chicago, IL 60625

Swedish Hospital (SW)

Cancer Center

5140 N. California Avenue, Suite G600-GMP,
Chicago, IL 60625

Swedish Hospital (SW)

Endeavor Health Medical Group

5215 N. California Avenue, Suite F801,
Chicago, IL 60625

Vernon Hills Specialty Suites (VH)

225 North Milwaukee Avenue,
Vernon Hills, IL 60061

Wilmette Medical Office (WM)

1515 Sheridan Road, Suite 31A,
Wilmette, IL 60091

Hospital locations:

Edward Hospital

801 S. Washington Street,
Naperville, IL 60540
(630) 527-3000

Elmhurst Hospital

155 E. Brush Hill Road,
Elmhurst, IL 60126
(331) 221-1000

Evanston Hospital

2650 Ridge Avenue,
Evanston, IL 60201
(847) 570-2000

Glenbrook Hospital

2100 Pflugsten Road,
Glenview, IL 60026
(847) 657-5800

Highland Park Hospital

777 Park Avenue West,
Highland Park, IL 60035
(847) 432-8000

**Northwest Community
Healthcare/Hospital**

800 West Central Road,
Arlington Heights, IL 60005
(847) 618-1000

Skokie Hospital

9600 Gross Point Road,
Skokie, IL 60076
(847) 677-9600

Swedish Hospital

5140 N. California Avenue,
Chicago, IL 60625
(773) 878-8200

Additional resources:

Endeavor Health Medical Group

1301 Central Street,
Evanston, IL 60201
(847) 570-5235

NorthShore Hospitals Foundation

1001 University Place, Suite 248
Evanston, IL 60201
(224) 364-7600

Endeavor Health Research Institute

1001 University Place,
Evanston, IL 60201
(224) 364-7100





Scan for more information

2025 Cancer Committee

Chairman

Seth Krantz, MD

Division Head, Thoracic
Surgery, Kellogg Cancer
Center

Physician Membership*

Bruce Brockstein, MD

Medical Director,
Kellogg Cancer Center
Head, Division of
Hematology/Oncology
Kellogg-Scanlon Chair
of Oncology

Francois Blumenfeld- Kouchner, MD

Division Head, Palliative Care

Carolina Soto Chervin, MD

Medical Director,
Cell Therapy

Elena Moore, MD

Kristian Novakovic, MD

Ajit Paintal, MD

Catherine Pesce, MD

Division Head,
Surgical Oncology

Cancer Liaison Physician

Monika Krezalek, MD

Director, Rectal Cancer
Program

Nicklas Pfanzelter, MD

Clinical Research
Coordinator
Quality Improvement
Coordinator

Carol Rosenberg, MD

Director,
Myra Rubenstein Weis
Living in the Future (LIFE)
Cancer Survivorship Program
Survivorship Program
Coordinator

Poornima Saha, MD

Arif Shaikh, MD

Radiation Oncology

Christine Tremper, MD

Diagnostic Radiology

Ancillary Membership

Luis Arellano

American Cancer Society

Kim Cholewa, BSN

Clinical Nurse Manager,
5S Searle

David Dahlman

Marketing Manager

Jamie Feld, MS/MPH, RN

Nurse Coordinator,
Cancer Committee

Jin Ko, LCSW, CCSW-MCS

Psychosocial Services
Coordinator

Lori Bumbaco, MS, RDN, CSO, LDN

Oncology Nutrition

Logan Brodsky

Oncology Support Services

Lindsay Cunningham

Director, Oncology
Operations

Sharon Huginnie

Senior Applications Analyst I
Epic IP/HOV Team
Health Information
Technology

Aviva Matanky, RN, OCN

Clinical Nurse Manager,
Evanston Kellogg Cancer
Center

Esha Kumar Nikore, PhD

Clinical Health Psychology

Sara Springer, MS, MBA

Cancer Program
Administrator,
Medical Group
Kellogg Cancer Center

Sabina Omercajic, MS, CCRP

Outreach Coordinator

Anisha Patel, APN

Clinical Coordinator,
MRW Living in the
Future (LIFE) Cancer
Survivorship Program

Dipale Patel, PharmD

Senior Director,
Oncology Pharmacy

Breanne Prindeville MS, CGC

Clinical Genetic Counselor

Savannah Ponders, RN, BSN, OCN

Oncology Nursing Director

Amanda Schell, MS, OTR/L

Rehabilitation Services

Debra Ziegler, MLIS, CTR

Cancer Registry
Quality Coordinator
Cancer Conference
Coordinator

* All academic affiliations are with the
University of Chicago Pritzker
School of Medicine